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Abstract 
 
In response to infection or tissue dysfunction, immune cells develop into highly heterogeneous 
repertoires with diverse functions. Capturing the full spectrum of these functions requires analysis of 
large numbers of effector molecules from single cells. However, currently only 3-5 functional proteins 
can be measured from single cells. We developed a single cell functional proteomics approach that 
integrates a microchip platform with multiplex cell purification. This approach can quantitate 20 proteins 
from >5,000 phenotypically pure single cells simultaneously. With a 1-million fold miniaturization, the 
system can detect down to ~100 molecules and requires only ~104 cells. Single cell functional proteomic 
analysis finds broad applications in basic, translational and clinical studies. In the three studies conducted, 
it yielded critical insights for understanding clinical cancer immunotherapy, inflammatory bowel disease 
(IBD) mechanism and hematopoietic stem cell (HSC) biology. 
To study phenotypically defined cell populations, single cell barcode microchips were coupled 
with upstream multiplex cell purification based on up to 11 parameters. Statistical algorithms were 
developed to process and model the high dimensional readouts. This analysis evaluates rare cells and is 
versatile for various cells and proteins. (1) We conducted an immune monitoring study of a phase 2 
cancer cellular immunotherapy clinical trial that used T-cell receptor (TCR) transgenic T cells as major 
therapeutics to treat metastatic melanoma. We evaluated the functional proteome of 4 antigen-specific, 
phenotypically defined T cell populations from peripheral blood of 3 patients across 8 time points. (2) 
Natural killer (NK) cells can play a protective role in chronic inflammation and their surface receptor – 
killer immunoglobulin-like receptor (KIR) – has been identified as a risk factor of IBD. We compared the 
functional behavior of NK cells that had differential KIR expressions. These NK cells were retrieved from 
the blood of 12 patients with different genetic backgrounds. (3) HSCs are the progenitors of immune cells 
and are thought to have no immediate functional capacity against pathogen. However, recent studies 
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identified expression of Toll-like receptors (TLRs) on HSCs. We studied the functional capacity of HSCs 
upon TLR activation. The comparison of HSCs from wild-type mice against those from genetics knock-
out mouse models elucidates the responding signaling pathway. 
In all three cases, we observed profound functional heterogeneity within phenotypically defined 
cells. Polyfunctional cells that conduct multiple functions also produce those proteins in large amounts. 
They dominate the immune response. In the cancer immunotherapy, the strong cytotoxic and antitumor 
functions from transgenic TCR T cells contributed to a ~30% tumor reduction immediately after the 
therapy. However, this infused immune response disappeared within 2-3 weeks. Later on, some patients 
gained a second antitumor response, consisted of the emergence of endogenous antitumor cytotoxic T 
cells and their production of multiple antitumor functions. These patients showed more effective long-
term tumor control. In the IBD mechanism study, we noticed that, compared with others, NK cells 
expressing KIR2DL3 receptor secreted a large array of effector proteins, such as TNF-α, CCLs and 
CXCLs. The functions from these cells regulated disease-contributing cells and protected host tissues. 
Their existence correlated with IBD disease susceptibility. In the HSC study, the HSCs exhibited 
functional capacity by producing TNF-α, IL-6 and GM-CSF. TLR stimulation activated the NF-κB 
signaling in HSCs. 
Single cell functional proteome contains rich information that is independent from the genome 
and transcriptome. In all three cases, functional proteomic evaluation uncovered critical biological 
insights that would not be resolved otherwise. The integrated single cell functional proteomic analysis 
constructed a detail kinetic picture of the immune response that took place during the clinical cancer 
immunotherapy. It revealed concrete functional evidence that connected genetics to IBD disease 
susceptibility. Further, it provided predictors that correlated with clinical responses and pathogenic 
outcomes.  
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Chapter 1 
Introduction 
 
The 21st century is the century of information. A transformation is taking place in almost every 
field. In biology and medicine, such a transformation leads to the emergence of “Systems Biology” and 
“Personalized Medicine”, where massive valuable information is being generated and is starting to 
provide insights to understand the complexity of human biology. 
Arguably, genomics is the first area in biology that benefits from this transformation. Nowadays, 
large scale genomics study has become commonplace in biology research. With the cost for genomic 
sequencing following the Moore law, it will not be long before whole genome sequencing become a 
common assay in the clinic. Advances in microfluidics and polymerase chain reaction (PCR) empowered 
this transformation. Just as what happened in the semiconductor industry, large scale integration and 
miniaturization enables assay replication at low cost. 
Proteomics represent yet another layer of information of the cells, as cells execute the majority of 
their biological function by proteins. However, proteomics study poses additional challenges. Unlike 
DNA, protein exhibits flexible, complex three dimensional structures that is important for its function. 
There is still not a universal assay that can comprehensively characterize this structure. The best reagent 
available to specifically and sensitively target proteins is still antibody. 
Immune cells protect the host against various pathogens and malignancy. They execute their 
functions and mediate immune response primarily by the expression and secretion of a myriad of 
functional proteins, collectively called cytokines. Although genetic and transcription analysis has 
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provided us with many insights, a direct measurement of immune functional proteomics has always been 
highly desirable. Traditionally, immunologists have been using surface markers characterized phenotypic 
information to imply immune cell function. Direct functional proteomics analysis has been limited to a 
very small number of cytokines, as one needs to related the measured secreted proteins back to their 
producer. 
Motivated by this challenge, in my graduate research, we combined microfluidics and antibody 
microarray to develop a new single cell microchip platform, called the Single Cell Barcode Chip. This 
technology compares favorably to current cellular immunoassays in terms of sensitivity, multiplexing 
capacity, quantitation, sample size, cost and infrastructure requirements. For the first time, we are able to 
comprehensively visualize the T cell functional proteomics. We observed profound single cell functional 
heterogeneity and showed the power of our single cell proteomics approach to capture this immune 
functional information. We also developed analysis method to interpret the new data and showed the 
value of the technology in three different research directions, ranging from basic animal model studies, 
translational human disease mechanism study and clinical study of cancer therapy phase II clinical trial. 
In the Chapter 2, I will review new technology that enables new understanding of single cell 
functional behavior. In Chapter 3, I will focus the Single Cell Barcode Chip, our solution for single cell 
proteomics analysis. I will also show proof-of-principle examples of its applications in this chapter. This 
work was published as a technical report in the journal Nature Medicine. 
The next chapter will devote to a comprehensive study of a phase 2 cancer immunotherapy 
clinical trial, where we studied multiple aspects of single cell behavior of the therapeutically active 
antitumor T cells used in the therapy by integrating many different technical platforms. We investigated 
the changes in function, number, phenotype of single cells over time and time-dependent changes of 
blood marker abundance. This study showed that although the phenotype and frequency of these cells 
changed uniformly across patients over time, the function of the antitumor T cells showed dramatically 
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different dynamics between patients, and, the differences are associated with the differences observed in 
patient’s clinical response. This study also points to interesting area to improve the antitumor therapy. 
The study is accepted as a research article in the journal Cancer Discovery. 
I will show another application of our technology towards the study of cellular functional disease 
mechanism of inflammatory bowel disease (IBD) in Chapter 5. We started with the genetic risk factors 
and used those insights to draw our hypothesis that natural killer cells developed in a particular genetic 
environment would confer a pro-inflammatory functional trait that promote T cell activity, which in turn 
will lead to IBD susceptibility. Then we proved it using our single cell technology as well as other 
biological methods. I will talk about NK cells, their genetics, their functions, as well as their interaction 
with helper T cells. This study helped us establish a cellular functional mechanism that accounts for IBD 
susceptibility. 
Finally, we will introduce the study of the hematopoietic stem cells and multi-potent progenitor 
cells in Chapter 6. We looked for immune effector functions of these cells and signaling pathways that 
lead to the cytokine production. We will also discuss the potential implications. 
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Chapter 2 
Single Cell Proteomics for Monitoring Immune 
Response in Cancer Therapy: Technology, Methods 
and Applications 
The field of targeted cancer therapeutics and immunotherapy has gone through significant 
maturation in recent years. For example, Ipilimumab, an antibody that blocks a T-cell function regulating 
surface receptor (CTLA-4) was approved by the Food & Drug Administration (FDA) for treatment of 
metastatic melanoma (1); Adoptive cell transfer therapy that utilizes T cells expressing transgenic T cell 
receptor (TCR) or chimeric antigen receptor (CAR) has demonstrated high objective response rate (>40%) 
in Phase II clinical trials (2); The newly approved small molecule drug, vemurafenib or PLX 4032, that 
targets BRAF oncogenic mutation (V600E), has been found to induce T-cell mediated antitumor response 
(3). Through these studies and other pre-clinical investigations, it has been increasingly recognized that 
immune cells play an important, yet paradoxical role in malignancy. Cytotoxic and helper T cells, natural 
killer cells and antigen presenting cells can mediate tumor destruction; whereas regulatory T cells, 
indoleamine-2.3-dyoxigenase (IDO) positive dendritic cells, and myeloid-derived suppressor cells 
(MDSCs) can protect malignancy (4, 5). Therefore, a deep understanding of the antitumor immune 
response and ways to control and maintain it are crucial for designing successful cancer therapeutics. 
Immune cells execute their functions primarily through the secretion of effector or signaling 
proteins, jointly called cytokines. Hundreds of such molecules have been found and these cytokines can 
mediate a myriad of functions, from direct target killing, to self-renewal, to recruitment of other immune 
cell types, and to promotion or inhibition of local inflammation. Further, due to the variety of the 
pathogens it needs to target, cellular immunity is inherently heterogeneous at the single cell level. 
Individual immune cells can possess differential capacities in producing these cytokines. Therefore, a 
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survey of immune cell function would require the development of high-throughput, highly multiple, 
single-cell assays that can profile the immune functional proteomics of single cells. An additional 
technical difficulty, the assays should have the capacity to relate the released proteins back to their 
cellular producers. 
In this review, we will focus on recent progresses in the development of single cell proteomics 
tools, with an emphasis to those that can be used as immune diagnostic and monitoring tools to cancer 
therapeutics. These technologies are necessarily sophisticated and generate large amounts of high-
dimensional protein readouts. Therefore, advanced data modeling and analysis methods that can help 
interpret and visualize the readout is highly desirable. We will review these useful methods for data 
processing, analysis and presentation in the second section. It is exciting that several technologies have 
been used to study primary human samples. Pilot studies using these technologies have provided a fresh 
view on the functional heterogeneity of immune cells and the dynamics of antitumor immune response. 
Therefore we will review some of the recent applications and propose potential roles of these 
technologies in cancer therapy. 
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Single Cell Proteomics tools  
Mass spectrometry in combination with liquid chromatography (MS-LC) was the first tool 
developed for proteomics studies. It is high-throughput and can potential reveal the full protein spectrum. 
Due to the limited amount of materials retrievable from single cells, the application of MS-LC towards 
single cells is challenging. Further, MS-LC requires input of fragmented or enzyme-digested samples and 
thus does not allow the recovery of viable cells for downstream usage. There have been exciting 
developments recently; however, the application of MS-LC in a clinical setting remains to be seen.  
Flow cytometry, invented in the 1970s, is one of the most advanced, versatile tools for studying 
single cells in immunology. It utilizes photon detectors to measure laser-activated fluorescence signals 
that are emitted from cells stained by fluorophore labeled antibodies and uses fluidics to hand the 
individual cells. The technology can be used to profile cell surface markers, phosphorylation during 
intracellular signaling and, to a limited capacity, cytokine production. With the increasing number of 
fluorophores available, currently 20 parameters can be measured; of them, up to 5 can be cytokines. Cells 
can be measured at a rate of up 10,000 per second, so the technology is high-thoughput. The potentially 
complicated calibration procedure to compensate the spectrum overlap of fluorophores has been 
standardization and automated. Multiple clinical centers have established centralized flow cytometry 
facilities. A version of flow cytometery, called fluorescence activated cell sorting (FACS), allows 
retrieving live cells with desired surface properties. Currently, as many as four cell populations can be 
purified in parallel. However, when it comes to measuring cytokine production, this technology is less 
optimal, due to its limited multiplexcity (<5), the required un-physiological blockage of protein secretion 
and non-viability of cells analyzed. 
One recent technical breakthrough along the direction of flow cytometry is mass cytometry, also 
known as cytometry by time-of-flight (cyTOF) (6). The technology is based on the detection of isotopes 
that do not naturally exist in biologically samples. Cells are stained by isotope-labeled antibodies and are 
then “evaporated” into clouds of molecules in the machine; thereby the isotope labeling is detected. The 
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application of this technology in immunology was first reported in 2011 (6). With proper combinatorial 
barcoding, the technology has been showed to detect 30 surface markers and 9 cytokines simultaneously. 
Unlike flow cytometry, whose multiplexity is limited by the overlap of fluorophore spectrum, mass 
cytometry can potentially detect a huge number of markers simultaneously (7). Currently, it is limited by 
a comparatively low-throughput and the low fraction of sample analyzable, but is expected to be 
improved (7). Because cells are “evaporated” during the assay, cells cannot be retrieved for downstream 
analysis. Thanks to many shared components and established experience available from flow cytometry, 
this technology grows very fast. It has been used to study the hierarchy of hematopoietic stem cell 
differentiation, the natural killer cell intracellular signaling and the T cell functional heterogeneity (6, 8, 
9), as we will review in a later section. 
The enzyme-linked immunosorbent spot (ELISpot) or fluorospot assay is a widely used quasi-
single cell technique. In the assay, cells are cultured on a petri dish that is pre-coated with cytokine-
specific antibodies. Cytokines released from individual cells are captured by surrounding antibodies. 
Subsequently, these captured cytokines are detected by applying secondary antibodies and fluorophore 
labels or through enzymatic reaction. After the assay, the number of spots on the petri dish, each relating 
to a cytokine producing cell, can be counted. It can achieve high sensitivity (<0.1%) and allows the 
detection of 3-5 cytokines at the same time. Because single cells are not separated when measured, the 
protein level cannot be quantitatively measured and single cannot be distinguished when cells are too 
close together. 
Recent developments in microfluidics have revolutionized the traditional ELISpot assay. These 
microchip-based technologies utilize arrays of highly miniaturized nano- to pico-liter volume micro-
chambers to achieve ultra-sensitive protein measurement and separation of single cells. Because single 
cells are separated in different micro-chambers, their protein levels can be quantitated in parallel. 1,000s 
to 10,000s micro-chambers can be integrated into one microchip, so the assay is high-throughput. The 
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amenability of these technologies to integrate with upstream cell purification and on-chip optical imaging 
further enhances their utility. Moreover, microchips are highly portable, low-cost and sample-efficient. 
One version of these microchips is called the single cell barcode chip (10). It couples a 
microfluidics-generated antibody microarray substrate with a microfluidics chip containing a large array 
of micro-chambers. The antibody microarray serves to detect cytokines secreted and the microchip is 
designed so that there is a full panel of antibodies within each micro-chamber. During the assay, single 
cells are separated into these 100-picoliter size micro-chambers. Because of a 1-million fold 
miniaturization, the microchip can achieve ultra-sensitivity down to 100 molecules and only requires 
10,000 cells as starting material. Currently, up to 20 – 40 proteins can be measured simultaneously from 5 
to 10 thousand single cells (11, 12) (Fan, unpublished data). The technology has been applied across 
many fields, including studying adaptive, innate immune cells, hematopoietic stem cells and intracellular 
signaling in malignancy. In particular, this technology has been used to study the functional heterogeneity 
of human T cells and clinical immune responses in an adoptive cell transfer immunotherapy to metastatic 
melanoma. 
Another version of the microchips employs the micro-engraving technique in fabricating micro-
chambers (13). In this technology, 25,000 (?) nano-liter sized micro-chambers can be integrated into one 
chip, wherein up to 3 types of cytokines can be measured by antibody on the substrate and at the same 
time cells can be stained by three colors. Immune cell – target cell interaction can be measured by on-chip 
imaging and temporal cytokine production profile can be acquired by periodically switching the antibody 
substrate (13, 14). This technology also has the capacity to retrieve viable individual cells with desirable 
properties from the microchip, as has been showed in the case of T cell cloning (15). Moreover, it has also 
been used to show the discordant cytokine production dynamics in human T cells (14). 
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Clinical applications and future directions  
The application of these new technologies has greatly advanced our understanding of the 
functional heterogeneity of immune cells. Initial studies (9, 10) on human T cells showed the existence of 
profound functional heterogeneity within a population of genetic and phenotypically similar T cells and 
that the level of functional heterogeneity reflects the functional activity of T cells. The functional 
heterogeneity has also been showed to be highly focused and the distribution of functional subsets is 
significantly different from a random distribution (9, 10). Thus, the functional heterogeneity contains 
valuable biological information, rather than pure noise.  
A new insight emerges from flow cytometry and microchip analysis is that cells simultaneously 
secreting a large number of cytokines, called the polyfunctional cells, also secreted each of these 
cytokines in large amounts (11, 16, 17). Thus, they produced a predominant amount of cytokine in an 
immune response. One explanation of this phenomenon is that the cytokine functions are coordinated at 
the level of single cells. Therefore, new parameters have been defined to summarize this information of 
polyfunctionality (11, 16, 17). These parameters have been found to correlate with the quality of T 
response in human and animal models (11, 16, 17). For example, an index, named polyfunctional strength 
index (pSI), is developed to summarize the joint functional intensity from polyfunctional T cells and its 
distribution among cytokines. A recent study extensively monitored the temporal changes of antitumor T 
cells retrieved from metastatic melanoma patients participating in a transgenic TCR adoptive cell transfer 
immunotherapy. By comparing the changes in the frequency, phenotype and polyfunctionality 
(summarized by pSI) of these T cells, the study showed that only the functional changes are highly 
distinguishable among patients and that the changes correlated with the clinical outcome (11). 
These studies demonstrated the importance to understand the functional heterogeneity of immune 
cells and its preliminary value in clinical diagnostics and monitoring. Because both the cellular immunity 
and tumor are heterogeneous at the single cell level, future successful cancer therapeutic scheme is 
necessarily personalized. Therefore, personalized diagnostic and monitoring tools, such as the single cell 
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functional analysis, are highly desirable and can be integrative components in different steps of cancer 
therapy. By understanding the functional characteristics of their immune cells, patients need to be 
stratified pre-treatment for the best available treatment; during the therapy, their immune response can be 
monitored and further intervention can be applied timely. The results obtained are feedbacks to guide 
further improvements of the therapy. 
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Chapter 3 
A clinical microchip for evaluation of single immune 
cells reveals high functional heterogeneity in 
phenotypically similar T Cells (10) 
 
Summary 
Cellular immunity has an inherent high level of functional heterogeneity. Capturing the full 
spectrum of these functions requires analysis of large numbers of effector molecules from single cells. We 
report on a microfluidic platform designed for highly multiplexed (>10), reliable, sample-efficient (~104 
cells) and quantitative measurements of secreted proteins from single cells. The platform was validated by 
assessment of multiple inflammatory cytokines from lipopolysaccharide-stimulated human macrophages, 
and comparison to standard immunotechnologies. We applied the platform towards the ex vivo 
quantitation of T cell polyfunctional diversity, via the simultaneous measurement of a dozen effector 
molecules secreted from tumor-antigen specific cytotoxic T lymphocytes (CTLs) that were actively 
responding to tumor, and compared against a cohort of healthy donor controls. We observed profound, yet 
focused, functional heterogeneity in active tumor-antigen specific CTLs, with major functional 
phenotypes quantitatively identified. The platform represents a novel and informative tool for immune 
monitoring and clinical assessment.  
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Introduction 
In response to infection or tissue dysfunction, immune cells develop into highly heterogeneous 
repertoires with diverse functions (16, 18-24). A homeostatic makeup of these functional phenotypes 
dictates the overarching effect of an immune response (16, 25, 26). For example, tumor infiltrating 
macrophages are activated to be either pro-inflammatory or regulatory depending on their interactions 
with other cells within the local microenvironment (27-30). Viral infection leads to activated T cells with 
a large variety of effector functions as reflected by different cytokine profiles (31, 32). Thus, a 
comprehensive characterization of the multifunctional phenotypes of single immune cells could provide 
both fundamental immunobiological information and clinically relevant data (21, 33).      
Common techniques for single cell protein assays include ELISpot (Fluorospot) and intracellular 
cytokine staining (ICS) flow cytometry (22).  For ELISpot assays, typically 1-3 secreted proteins are 
detected at the single cell level. The approach can be quantitative for detecting cytokine secreting cells, 
but it is not quantitative for the secreted protein levels. ICS flow cytometry has enabled the detection of 
up to 5 cytokines from single cells. Measurements of polyfunctionality may provide a better indication of 
in vivo activity, relative to phenotypic classifications based upon cell surface markers (16). This implies 
the need for measurements of increasing numbers of functions, via multiplex protein assays, from single 
cells.  
Herein, we report on the Single Cell Barcode Chip (SCBC), for the high-content assessment of 
functional heterogeneity at the single cell level. The chip is comprised of 1,040 3-nanoliter volume 
microchambers, and each loaded with single cells or small defined numbers of cells.  Protein levels are 
measured using immuno-sandwich assays from a spatially encoded antibody barcode.  A full barcode 
represents a complete panel of protein assays, and duplicate barcodes per microchamber enable 
measurement statistics at the single cell level. The SCBC permits on-chip, highly multiplexed detection of 
sub-thousand copies of proteins and requires only ~104 cells to perform the assay.   
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The technique was validated using a human macrophage cell line to demonstrate single cell 
detection of multiple cytokines. We then implemented it to assay the polyfunctionality of tumor-antigen-
specific T cells in the setting of an adoptive cell transfer (ACT) therapy clinical trial for melanoma. We 
observed focused, yet highly heterogeneous, functional diversity compared to samples from healthy donor 
controls. The SCBC is a high-throughput, low-cost, and portable platform that can find a wide range of 
fundamental and clinical applications in understanding disease mechanism and therapeutics.  
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RESULTS 
Single cell barcode chip: design rationale and detection limit 
The SCBC system consists of four modules (Figure 1): microchannels that contain cells, control 
valves that isolate cells into microchambers, inlet and outlet ports for the introduction and depletion of 
reagents and cells, and a barcode-encoded glass substrate for protein detection. The chip itself consists of 
two PDMS layers, and fits onto a microscope slide (Figure 1a). The lower PDMS layer has inlets for the 
loading of reagents and cells which branch into 80 microchannels of 100 µm × 17 µm cross-section. 
Thirteen sets of vertical valves on the top PDMS layer divide those microchannels into 1,040 nanoliter-
volume microchambers. For a microchamber containing 1-10 cells, the cell density is 0.3-3×106 cells ml-1, 
falling into the normal range for culture conditions and physiological environments (34). 
 The barcode array is a pattern of parallel stripes, each coated with a distinctive antibody. The 
stripe width is 25 µm at a pitch of 50 µm. To achieve high and consistent antibody loading, and to prevent 
antibody denaturation during microfluidics assembly, the DNA-encoded antibody library (DEAL) 
approach (34), coupled with microchannel-guided flow patterning (35), was utilized (Supplementary 
Figure 1). The chemistry and reproducibility of the DNA barcode patterning process has been previously 
described (35-37). The SCBC barcodes contain 13 stripes, 12 for assaying a dozen different proteins, and 
one as a control and spatial reference. Two sets of barcodes are included per microchamber. Cells are 
randomly loaded so that each SCBC microchamber contains zero to a few cells, following a Gamma 
Poisson distribution (Goodness-of-Fit test: P > 0.8. Supplementary Figure 2). The numbers of cells in 
each chamber are counted via imaging (Figure 1b).   
We determined the dynamic range and detection limit of our design by performing on-chip 
immunoassays with recombinant proteins (Figure 1c). The barcode array initially consists of 13 uniquely 
designed orthogonal DNA strands labeled in order as A through M (Supplementary Table 1).  Prior to 
loading recombinant proteins,  a cocktail containing all capture antibodies conjugated to different 
complementary DNA strands (A’—L’) is used to transform, via DNA-hybridization, the DNA barcode 
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into an antibody array (Figure 1c). As few as 102-103 copies (10-22-10-21 mol) could be detected (3 
standard deviations), with a dynamic range of 3-4 orders of magnitude (Figure 1e, Supplementary 
Figure 3), which is compatible with single cell secretion measurements (34). Antibody loading, and thus 
assay sensitivity, is uniform across the whole chip (coefficient of variation (C.V.) <10%) (Figure 1d–e).  
 
 
Figure 1 Design of the Single Cell Barcode Chip (SCBC) for single cell protein secretome analysis. 
(a) Image of an SCBC in which flow channels are shown in red and the control channels are shown in 
blue. Input and output ports are labeled.  (b) An optical micrograph showing cells loaded and isolated 
within the microchambers, overlaid with the fluorescence micrograph of the developed assay barcode for 
those same microchambers.  Numbers of cells per microchamber are indicated by the yellow numbers. (c) 
Drawing of the multiplex DEAL 1o antibody barcode array used for capture of secreted proteins from 
single cells and then developed for the detection of those proteins. (d) Scanned fluorescent images used 
for the antibody barcode calibration measurements using spiked recombinant proteins. The protein 
concentrations (in numbers of molecules per chamber) are given to the left of each row of images. The 
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plot at the top is a line profile of the top row of images, and represents the reproducibility of the barcodes 
across the antibody array of an SCBC. (e) Recombinant protein calibration curves for TNF-α, IL-1β, IL-6, 
IL-10 and GM-CSF. Individual measurements (red) are shown for IL-1β.  Other proteins measurements 
are represented by average intensity values and standard deviations. 
 
 
 
Supplementary Figure 1 Fabrication of the DNA barcode array. (a) Schematic illustration of the 
microchannel-guided flow patterning techniques. (b) AutoCAD design of the photolithographic mask 
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used for patterning a high-density DNA barcode array. A-M are the labels of primary DNA molecules. (c) 
Test result for hybridization to individual fluorescent Cy3-labeled complementary DNA showing 
negligible cross-reactivity (<1% in photon counts). (d) individual channels flowed by different 
recombinant proteins. 
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Supplementary Figure 2 Distribution of number of cells across the whole chip, fitted to Gamma 
Poisson distribution. 
 
 
 
 
Supplementary Figure 3 Fluorescence quantitation curves for proteins measured from T cells.  
 
Supplemental Table 1. Sequences and terminal functionalization of oligonucleotides*.  
Name            Sequence        Melting Point 
A 5'- AAA AAA AAA AAA AAT CCT GGA GCT AAG TCC GTA-3' 57.9 
A' 5' NH3- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT-3' 57.2 
B 5'-AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'- AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'-AAA AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
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D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'-AAA AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
F 5'-AAA AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA -3' 56.9 
F' 5' NH3-AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT -3' 56.1 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
I 5'-AAA AAA AAA ATG CCC TAT TGT TGC GTC GGA-3' 60.1 
I' 5' NH3-AAA AAA AAA ATC CGA CGC AAC AAT AGG GCA-3' 60.1 
J 5'-AAA AAA AAA ATC TTC TAG TTG TCG AGC AGG-3' 56.5 
J' 5' NH3-AAA AAA AAA ACC TGC TCG ACA ACT AGA AGA-3' 57.5 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-Cy3-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' NH3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
 
* all oligonucleotides were synthesized by Integrated DNA Technology (IDT) and purified via high performance 
liquid chromatography (HPLC).  
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Analysis of cytokine production by LPS-stimulated macrophages  
We validated the SCBC by using the human monocyte cell line, THP-1. The THP-1 cells were 
differentiated into cytokine-producing macrophages using phorbol 12-myristate 13-acetate (PMA). Before 
loading into the device, lipopolysaccharide (LPS) was added to activate the Toll-like Receptor-4 (TLR4) 
signaling (38, 39), a process that mimics the innate immune response to Gram-negative bacteria 
(Supplementary Figure 4). For these experiments, the antibody barcode was designed to measure 12 
proteins: tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), IL-1α, IL-1β, IL-6, 
IL-10, IL-12, granulocyte macrophage-colony stimulating factor (GM-CSF), chemokine (C-C motif) 
ligand-2 (CCL-2/MCP-1), transforming growth factor-β (TGF-β), and prostate specific antigen (PSA) 
(Supplementary Table 2).  
The microchambers contained between 0-40 cells so that both single cell behavior and signals 
from a population could be measured. Through an automated image processing algorithm, we quantified 
the fluorescence intensities for each protein from each microchamber. For chambers with cells centered 
between the two barcodes, measurements from the barcode replicates are consistent (C.V. < 15%, Figure 
2). Un-centered cells contribute to variance between replicates (C.V. up to 50%); however, averages of 
the barcode replicates from chambers with centered and un-centered cells are indistinguishable (P > 0.2, 
Supplementary Figure 5). Furthermore, measurements between chips displayed good consistency (P > 
0.2). 
The intensities of the individual proteins, averaged over many individual SCBC microchamber 
measurements, agreed with measurements of those same proteins from cell culture supernatants (Figure 
2a). Secretome data, when binned according to the numbers of cells per chamber, yielded statistically 
distinct protein signals (P < 0.05, Figure 2b and Supplementary Figure 6). However, the reference 
signal was insensitive to the numbers of cells (P > 0.2, Figure 2b and Supplementary Figure 6). Most 
notably, single cell protein signals can be clearly detected (P < 0.0001, Figure 2b and Supplementary 
Figure 6). Clear separation of secreting and non-secreting cells is also visualized by multiple peaks in the 
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histograms provided in Figure 2c.  
The fraction of cells detected to secrete a given protein was gated using background signals from 
empty chambers. The frequency of TNF-α, IL-1β, IL-10 and GM-CSF producing cells were measured to 
be similar by both SCBC and by ICS flow cytometry (Figure 2c and Supplementary Figure 6). 
Furthermore, the measured fraction of cells in each quadrant also shows a good similarity between the 
two techniques (Figure 2c and Supplementary Figure 6). Thus, the SCBC platform can efficiently 
provide a functional profiling of single immune cells. 
 
 
Figure 2. On chip secretion measurements of macrophage differentiated from THP-1 monocyte cell. 
(a) Left. Representative scanned images of barcode signals from individual chambers. Green bars 
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represent microchamber boundaries, red bars are protein signals, and the yellow numbers indicate the 
number of cells. Right. Comparison of averaged intensity from SCBC measurements and bulk culture 
supernatant. Data is normalized so that references have the same intensity. (b) Scatterplots of measured 
levels of TNF-α and the reference control, for individual microchambers containing n = 0,1,2,3,4,5 cells. 
P values are calculated by comparing neighboring columns (* P < 0.005; ** P < 0.001; *** P < 0.0001; 
NS not significant.). (c) Scatterplots of TNF-α v.s. IL-1β derived from SCBC measurements (left) and 
from ICS coupled with flow cytometry (right). Histograms (frequency v.s. intensity) for the individual 
protein are provided at the top and sides of the scatterplots.  All y-axis units are fluorescence intensity.  
For the SCBC data, each quadrant is labeled with numbers that reflect the % of single cells (red) and 2-3 
cells (green) in that section. The gates separating cytokine secreting and non-secreting cells are 
determined from 0 cell microchamber (background) measurements (blue). Standard deviations from 
barcode replicates of the same chamber are provided for selected points (see text for selection criteria). 
For the ICS measurements the gates were determined by isotype control staining.  
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Supplementary Figure 4 Morphology change of THP-1 cell upon PMA/LPS activation. The upper 
panels are lower magnification optical images and the lower panels are viewed at a higher magnification. 
The morphological change from non-adherent to adherent phenotypes was observed upon PMA/LPS 
treatment.   
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Supplementary Figure 5 Averaged signals detected from cells located in middle of the chamber vs. 
cells on the edge (p>0.2). 
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Supplementary Figure 6 On chip secretion measurements of macrophage differentiated from THP-
1 monocyte cell. (a) Scatterplots of measured levels of IL-1β, for individual microchambers containing n 
= 0,1,2,3,4,5 cells. P values are calculated by comparing neighboring columns (* P < 0.005; ** P < 0.001; 
*** P < 0.0001; NS not significant.). (b) Histogram comparisons of SCBC and ICS for IL10 and GMCSF. 
 
Supplementary Table 2. Summary of antibodies used for macrophage experiments. 
 
DNA label primary antibody (vendor: clone)  secondary antibody (vendor: clone) 
A’  mouse anti-hu IFN-γ (eBio:  MD-1)  biotin-labeled mouse anti-hu IFN-γ (eBio: 4S.B3 ) 
B’  mouse anti-hu TNF-α (eBio: Mab1)  biotin-labeled mouse anti-hu TNF-α (eBio: Mab11) 
C’  mouse anti-hu IL-2 (eBio: MQ1-17H12 )  biotin-labeled mouse anti-hu IL-2 (eBio:  polyclonal) 
D’  mouse anti-hu IL-1α (eBio: CRM8 )  biotin-labeled mouse anti-hu IL-1α (eBio:  CRM6) 
E’  mouse anti-hu IL-1β (eBio: CRM56)  biotin-labeled mouse anti-hu IL-1β (eBio: CRM57) 
F’  mouse anti-hu TGF-β (eBio: TB2F)  biotin-labeled mouse anti-hu TGF-β (eBio: 16TFB) 
G’  mouse anti-hu PSA (BioDesign: S6  )  biotin-labeled mouse anti-hu PSA (BioDesign: S2 ) 
H’  mouse anti-hu IL-6 (eBio: MQ2-13A5)  biotin-labeled mouse anti-hu IL-6 (eBio: MQ2-39C3) 
I’  mouse anti-hu IL-10 (eBio: JES3-9D7)  biotin-labeled mouse anti-hu IL-10 (eBio:  JES3-12G8) 
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J’  mouse anti-hu IL-12 (p70) (eBio: BT21)  biotin-labeled mouse anti-hu IL-12 (eBio: C8.6 ) 
K’ mouse anti-hu GM-CSF (BD)   biotin-labeled mouse anti-hu GM-CSF-γ (BD) ∗∗ 
L’  mouse anti-hu MCP-1(eBio: 5D3-F7)  biotin-labeled mouse anti-hu MCP-1(eBio: 2H5 ) 
** BD OptEIA ELISA Set, Catalog No. 555126. 
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Analysis of poly-cytokine production by human cytotoxic T lymphocytes  
 We now turn towards utilizing the SCBC to functionally profile antigen specific CTLs, which are 
the main effector cell type of an adaptive immune response targeting intracellular pathogens and tumors 
(40). CTLs can exhibit a great diversity of antigen specificities, phenotypic surface proteins, and 
functions.  Capturing this diversity is a significant challenge. Previous data suggests that the ability of 
CTLs to produce multiple cytokines (polyfunctionality) correlates with protective immune responses in 
vivo (16, 41, 42).  
We assayed the functional diversity of healthy donor CD8+ T cells (n = 3), MART-1-specific T 
cell receptor (TCR) transgenic cells harvested from the peripheral blood of a patient with metastatic 
melanoma participating in an adoptive cell transfer (ACT) immunotherapy clinical trial, and of ex vivo 
expanded tyrosinase-specific T cells. TCR engineering provides a means to generate large quantitites of 
antigen-specific T cells amenable to use for the therapy of cancer (43). The TCR transgenic cells 
collected from peripheral blood of a patient had been previously generated in vitro by retroviral vector 
transduction to insert the two chains of a TCR specific for MART-1, then expanded ex vivo for two days 
followed by re-infusion into the patient after a lymphodepletion conditioning regimen. The patient then 
received three vaccinations with dendritic cells pulsed with a MART-1 peptide and high dose IL-2 to 
further activate and expand the cells in vivo. Peripheral blood mononuclear cells (PBMCs) were harvested 
on day 30 following re-infusion by leukapheresis, at a time when multiple metastatic melanoma lesions 
were responding to this therapy. The tyrosinase-specific T cell culture was generated ex vivo from a 
tyrosinase-specific cell culture obtained by peptide/HLA-A0201 tetramer based selection followed by 
non-specific expansion with CD3 antibody and IL-2 to obtain a population of non-transgenic but uniform 
antigen-specific T cells.  
PBMCs were enriched for CD3 markers by negative magnetic beads selection before sorting on 
DEAL-based CD8 antibody or peptide/HLA-A0201 tetramer coated microarrays (44). Then CD3+CD8+ 
or CD3+tetramer+ cells were released from the microarrays. The released T cells underwent activation 
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either by polyclonal TCR engagement of CD3 and CD28 antibody binding or antigen-specific TCR 
engagement via tetramer and CD28 antibody, respectively. Activation and SCBC loading was completed 
within 5 minutes. To maximize the percentage of single cell measurement to 25-40%, ~104 sorted T cells 
in 5µl media were loaded into the device.  Protein heat maps and plots that compare and contrast these 
different T cell groups are presented in Figure 3. Multiple markers that indicate functions such as 
cytoxicity (perforin), T cell growth and differentiation (IL-2), apoptosis promotion (TNF-α, IFN-γ), 
inflammation (IL-1β, IL-6, TNF-β), anti-inflammation (IL-10), and the stimulation and recruitment of 
other immune compartments (CCL-2/MCP-1, CCL-3/MIP-1α, CCL-5/RANTES, GM-CSF) (42), were 
included in the T cell panel (Figure 3 and Supplementary Table 3).  
More than 20% (median) of the healthy donor CD3+CD8+ T cells produced TNF-α, IL-6 and 
three chemokines CCL-2, CCL-3 and CCL-5. The MART-1-specific TCR transgenic cells that were 
inducing an objective tumor response in vivo exhibited a wide range of positive functions demonstrated 
by the release of perforin, IL-1β, IL-10, IFN-γ, IL-2 and CCL-5 upon ex vivo antigen restimulation with 
the MART-1/HLA-A0201 tetramer. The functionality of the antigen-specific patient-derived TCR 
transgenic cells was higher compared to the healthy donor lymphocytes in terms of both signal intensity 
and fraction of positive cells (Figure 3a-b, e). The frequency of cytokine-producing cells among the 
patient-derived TCR transgenic cells was consistent with Fluorospot results (Figure 3d). Phenotyping 
results identified by flow cytometry on surface markers of T cell phenotype (Figure 3c)  illustrated that 
the population of patient-derived TCR transgenic MART-1-specific cells was mostly homogeneous; the 
principal (>90%) population these cells was CD8+ and had a phenotype consistent with effector TEMRA 
cells at a late differentiation stage (Figure 3c) (31). In comparison, the ex vivo expanded tyrosinase-
specific T cells exhibited decreased production of CCL-3, IL-6 and TNF-α. Consistent with the notion 
that ex vivo expansion of T cells by IL-2 and CD3 antibody results in terminal differentiation of T cells, 
the tyrosinase-specific T cell clone had elevated release of perforin, IL-1β and IL-2, compared to healthy 
control samples, upon exposure to their cognate antigen (Figure 3e and Supplementary Figure 7).   
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Figure 3 Single cell secretion measurements of CTLs from melanoma patients and healthy donors. 
(a) Unsupervised clustering of CD8+ T cells from three healthy donors, presented as a heat map. Each 
row represents a measurement of 12 secreted cytokines from a single cell, with protein labels provided at 
the bottom. (b) Data from MART-1-specific TCR transgenic CTLs single cell experiments, presented as a 
heat map organized via unsupervised clustering. The fluorescence intensity scale for all 4 heat maps is the 
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same. (c) Phenotyping data from flow cytometry for MART-1-specific TCR transgenic CTLs. Each bar 
shows the percentage of cells positive for the specific surface marker. (d) Fluorospot analysis of the 
MART-1-specific TCR transgenic T cell population. The curves on top compare SCBC and Fluorospot 
measurements on fraction (or number) of cells secreting CCL-2, CCL-5, perforin, IL-1β, IL-6 and TNF-α. 
Representative Fluorospot images are provided below. (e) Univariate comparison of patient-derived 
antigen specific TCR transgenic T cells and healthy donor CD8+ T cell culture controls. The lines of the 
top plot represent the percentage of cytokine producing cells from each sample. Blue area shows the 
range detected from healthy donor samples. The one-dimensional scatter plot on the bottom compares the 
signal intensities measured from the patient’s  MART-1-specific TCR transgenic T cells and the CD8+ T 
cell background from one representative healthy donor. 
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Supplementary Figure 7 Univariate comparison among CTLs from healthy donors (a), CD3+ 
MART-1-specific CTLs and CD3+ Tyrosinase-specific CTLs from melanoma patients (b). 
 
Supplementary Table 3. Summary of antibodies used for patient T cell experiments. 
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DNA label primary antibody (vendor: clone)  secondary antibody (vendor: clone) 
A’  mouse anti-hu IFN-γ (R&D)   biotin-labeled mouse anti-hu IFN-γ (R&D ) 
B’  mouse anti-hu TNF-α (R&D)   biotin-labeled mouse anti-hu TNF-α (R&D) 
C’  mouse anti-hu IL-2 (R&D)   biotin-labeled mouse anti-hu IL-2 ( R&D ) 
D’  mouse anti-hu TNF-β (eBio: 359-238-8)  biotin-labeled mouse anti-hu TNF-β (eBio:  359-81-11) 
E’  mouse anti-hu CCL5 (R&D)      biotin-labeled mouse anti-hu CCL5 (R&D) 
F’  mouse anti-hu Perforin (Abcam)  biotin-labeled mouse anti-hu Perforin (Abcam) 
G’  mouse anti-hu IL-1β ( R&D )   biotin-labeled mouse anti-hu IL-1β ( R&D ) 
H’  mouse anti-hu IL-6 (R&D)   biotin-labeled mouse anti-hu IL-6 ( R&D ) 
I’  mouse anti-hu IL-10 (R&D)   biotin-labeled mouse anti-hu IL-10 ( R&D ) 
J’  mouse anti-hu MCP-1(eBio: 5D3-F7)  biotin-labeled mouse anti-hu MCP-1(eBio: 2H5 ) 
K’  mouse anti-hu GM-CSF (eBio: BVD2-23B6) biotin-labeled mouse anti-hu GM-CSF (BVD2-21C11) 
L’  mouse anti-hu CCL3 (R&D)   biotin-labeled mouse anti-hu CCL3 (R&D) 
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Evaluation of polyfunctionality 
We analyzed the multivariate features of these T cell populations by studying the protein-protein 
correlations for 2 and 3 proteins. Pseudo-3D plots (Figure 4a—c) of markers representing different 
functions revealed that certain functions of the MART-1-specific cell population were highly coordinated 
compared to the healthy donor cells. For example, 70% of IL-6+ cells produce CCL-5, whereas for CTLs 
from healthy donors the frequency is around 50%. TNF-α and IFN-γ production are anti-correlated in 
MART-1-specific cells (Figure 4c), with >90% of the population expressing at most one of these effector 
molecules. However, for the small fraction of MART-1-specific TCR transgenic cells that were TNF-
α+IFN-γ+, secretion of IL-2 is often an additional function (75%, Figure 4). A full set of protein-protein 
correlations is provided in Supplementary Figure 8.   
We defined functional subsets of the various T cells by identifying groups of cells that secrete the 
same combination of proteins (Figure 4d—e). At least 45 distinct sub-populations are required to account 
for 60% of the MART-1-specific TCR transgenic cells (Figure 4e and Table 1).  A similar accounting 
for the healthy donor CD8+ T cells and the tyrosinase-specific T-cells yields 4-17 sub-populations 
(Figure 4d and Table 1). Furthermore, for the MART-1-specific TCR transgenic cells, the major 
functional subsets averaged more than 5 active functions. By contrast, both healthy donor and tyrosinase-
specific cells averaged only 1-2 functions (Table 1). This demonstrates the ability of SCBC to visualize 
and discriminate different levels of functional heterogeneity. 
 
- 34 - 
 
 
Figure 4 Polyfunctional diversity analysis for CTLs from a patient with metastatic melanoma and 
from healthy donors. (a—c) Pseudo three dimensional scatterplots for representative single cell cytokine 
measurements from CD8+ T cells. Upper and lower rows are correlations for perforin vs. IL-6 and TNF-α 
vs. IFN-γ, respectively. The third dimension (CCL-5 or IL-2) is projected to the 2D plot by using red for 
positive cells and blue for negative cells. Numbers on the right show percentage in each quadrant. 
Samples are labeled on the left. (d—e) Functional diversity plots for patient’s MART-1-specific TCR 
transgenic cells and CD8+ T cells from a representative healthy donor. Each major functional subset 
identified (with frequency >0.5%) is shown by an individual bar. The bar heights represent population 
percentages. 53 major subsets were identified from the MART-1-specific TCR transgenic cells; 23 were 
identified from the healthy donor. The number on top of the plot shows number of functions associated 
with each subset.  The matrix below provides the function detail (X: positive). The pie charts give the 
percentage of cells that fell into one of the major functional subsets. Asterisks above the blue bars denote 
those subsets within the most frequent 60% of the population.  
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Table 1 Summary of functional diversity of assayed samples 
Sample 
Major 
functional 
subsets 
identified 
Percentage 
of total 
populations 
Number of 
function 
Functional 
subsets in 
top 60% 
populations 
Number of 
function 
Range Mean Range Mean 
Healthy 
CD3+ 
CD8+ 
1 33 70.3 0-7 1.68 17 0-5 1.32 
81 23 77.4 0-7 1.44 6 0-6 1.34 
6 21 80.2 0-7 0.89 4 0-2 0.36 
Subject 
CD3+ 
MART1+ 
53 63.4 0-12 5.17 45 1-12 5.27 
Subject 
CD3+ 
Tyrosinase+ 
(Cultured) 
27 80.1 0-5 2.25 8 0-4 2.11 
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Scatterplot for CTLs from healthy donor controls (n=3) 
#1 
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Scatterplot for MART-1 T Cells 
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Scatterplot for Tyrosinase T Cells 
 
 
Supplementary Figure 8.  Protein-protein correlation plot matrices from single cell experiments of 
CTLs from healthy donor controls, MART1 T cells and Tyrosinase T cells. 
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DISCUSSION 
The SCBC permits highly multiplexed (> 10) measurements of effector molecules from single 
cells by detecting the natural protein secretome from macrophages and T cells upon activation. The 
multiplex capacity can be further expanded beyond what was explored here, as will be showed in later 
chapters. The ability to use small sample size (~104 cells) implies that the SCBC can be integrated with 
other upstream multiplexed analysis, such as flow cytometry or, as demonstrated, microarray sorting, to 
enable a detailed functional study of phenotypically defined sets of cells selected from heterogeneous 
populations. Analysis of signals from chambers containing different numbers of cells may also provide 
information relevant to cell-cell interactions.  
The MART-1-specific TCR transgenic CTLs had stronger perforin, IFN-γ and interleukin 
secretion and higher level functional heterogeneity compared with the healthy donor CTL controls. This 
functional status is also indicated by their identity as effector T cells (CD45RA+, CCL7-, CD27-, CD28-, 
CD62L-) (31, 45, 46). Previous vaccination studies identified that polyfunctional T cells are better 
cytokine producers, and that the quality of a polyfunctional T cell response is a good predictor of clinical 
outcome (16, 47). We found that the MART-1-specific TCR transgenic CTLs exhibit favorable features 
compared against CTLs from healthy donors (e.g. polyfunctional subset frequency 62% v.s. 6-25% and 
Supplementary Figure 9). These data are consistent with the observation that, at the time the CTLs were 
harvested, there was active inflammation and the tumors were responding to the ACT therapy in this 
patient.  
We observed signs of T cell terminal effector differentiation and exhaustion, as indicated by the 
anti-correlation of TNF-α and IFN-γ secretion, high IL-10+ cell frequency, and high PD1 and CD127 
expression (31). However, the quality of the T cell response at a single time point within a vaccination 
trial may not provide an indicator of long term vaccination or therapy response (16). A similar multi-
parametric SCBC analysis, but carried out at multiple time points throughout the course of a cancer 
immunotherapy treatment, will be described in later chapters. 
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We saw a high level of functional heterogeneity within a population defined as relatively 
homogeneous by surface markers (40, 48), and that heterogeneity is also focused. For example, the top 60% 
of the MART-1-specific TCR transgenic cells fell into 45 out of >4000 (212) possible functional subsets. 
The observed high level of polyfunctionality (up to 12 functions per cell, with an average of >5 functions) 
exceeds current multiplexing capacity by most existing single cell secretion assays. Moreover, we note 
that none of the proteins being profiled were interchangeable with others within the panel (with R2 < 0.6, 
Supplementary Figure 8). These findings indicate that a high dimensional analysis is in fact required for 
comprehensively profiling of T cell effector functions. 
The SCBC provides a novel platform for analyzing the functional activity of immune cells 
immediately following short term ex vivo activation. This technology compares favorably to current 
cellular immunoassays in terms of sensitivity, multiplexing capacity, quantitation, sample size, cost and 
infrastructure requirements, and thus has potential for a thorough, cost-effective characterization of 
patient immune cell responses. 
 
 
 
Supplementary Figure 9 Ratio of averaged functional intensity of polyfunctional T cells (n > 4) to 
non-polyfunctional T cells (n ≤ 4).  
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METHODS 
Microchip Fabrication. The SCBCs were assembled from a DNA barcode microarray glass slide and a 
PDMS slab containing a microfluidic circuit. The DNA barcode array was created with microchannel-
guided flow patterning (Supplementary Fig. 1). Each barcode was comprised of thirteen stripes of 
uniquely designed ssDNA molecules. PDMS microfluidic chip was fabricated using a two-layer soft 
lithography approach(49) (Supplementary Methods). 
Human samples. Human samples were obtained from patients with metastatic melanoma enrolled in a T 
cell receptor (TCR) transgenic ACT protocol clinical trial registration number (NCT00910650). The 
study using Human sample were approved by the appropriate human use committees (UCLA IRB# 08-
02-020, IND# 13859), and informed consent was obtained from all subjects studied. 
Isolation, purification and expansion of T cells. PBMC were collected from patients receiving TCR 
engineering ACT immunotherapy by leukapheresis and periodic peripheral blood draws as previously 
described(50). Aliquots of cryopreserved PBMC thawed and immediately diluted with RPMI complete 
media containing 5% human AB serum (Omega Scientific). Cells were washed and subjected to 
enzymatic treatment with DNase (Sigma) for 1 hour at 37°C, washed and rested overnight in a 5% CO2 
incubator. Antigen-specific MART-1 T cells were purified sequentially by magnetic negatively 
enrichment for CD3 (Stemcell) and by MART-1/HLA-A0201 tetramer microarray that have been 
previously described(44) (Supplementary Methods). Purified cells were collected, washed, stimulated 
with MART-1 tetramer/CD28 antibody and loaded into SCBC chip. PBMC from healthy donor were 
negatively enriched in the same way and were further purified by CD8 antibody microarray, followed by 
stimulation with CD3/CD28 antibody. Sorted cells was checked to be >95% pure. 
On-chip secretion profiling. Prior to loading cells on chip, the DNA barcode array was transformed into 
an antibody microarray through the following steps. The chip is then ready for cell loading. Chips with 
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cells were incubated and then assays were developed with secondary antibodies and fluorescent markers 
(Supplementary Methods).  
Intracellular cytokine staining of THP-1 cells. Brefeldin A (eBioscience) was added in the presence of 
PMA and LPS at recommended concentration in the final 4h of stimulation. Standard intracellular 
staining was performed as described by supplier’s protocol (eBioscience) with additional blocking with 
human serum (Sigma) and washes. Cells were fixed and permeabilized by using a fixation and 
permeabilization kit (eBioscience) and then were stained intracellularly with αTNFα (MAb11), αIL-
1β (H1b-98), αIL-10 (JES3-9D7) and αGM-CSF (BVD2-21C11). Isotype control staining was used as 
negative control and 2 x 104 events were collected for each condition. Samples were analyzed on a 
FACSCalibur (BD Biosciences) machine with CellQuest Pro software (BD Biosciences).  
Flow cytometry analysis of antigen specific T cells. Cryopreserved PBMC samples from peripheral 
blood draws or leukapheresis were thawed and analyzed by HLA-A*0201 tetramer assay (Beckman 
Coulter) with flow cytometric analysis as previously described(50, 51). In brief, PBMCs were 
resuspended in 100 µl of adult bovine serum (Omega Scientific) and stained for 15 minutes at room 
temperature using a cocktail of antibodies: CD45RA, CCR7, CD62L, CD27, CD28, PD-1, CD127 in 
replicate aliquots. For all flow cytometry experiments, anti-mouse Igk/Negative Control FBS 
compensation particles (BD Biosciences) were used for compensation purpose, and 5 x 105 to 1 x 106 
lymphocytes were acquired for each condition. In order to correctly gate the flow cytometry data, the 
fluorescent minus one (FMO) approach was used. Samples were acquired on a LSR II systems (BD 
Biosciences) and data was analyzed using FlowJo software (TreeStar). 
Fluorospot assay for sorted antigen specific T cells. Antigen specific T cells were captured by tetramer 
microarray.  Primary cytokine capture antibody was co-localized on the same array. The captured cells 
were then incubated at 37 degree/5% CO2 for 12 hours in 10% FBS/RPMI 1640 media. PE labeled 
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secondary antibody was applied after incubation. Then slides were washed and imaged by EZ-C1 
confocal microscope systems (Nikon). 
Data analysis and statistics. We used GenePix 4400 (Axon Instruments) to obtained the scanned 
fluoresce image for both Cy3 and Cy5 channels. All scans were performed at constant instrument settings: 
laser power 80% (635 nm) and 15% (532 nm), optical gains 600 (635 nm) and 450 (532nm), brightness 
80 and contrast 83 for T cell experiment and laser power 100% (635 nm) and 33% (532 nm), optical gains 
800 (635 nm) and 700 (532nm), brightness 87 and contrast 88 for macrophage experiment. All the 
barcodes were processed in PhotoShop (Adobe) and ImageJ software (NIH) to generate fluorescence line 
profiles. A home-developed Excel (MicroSoft) macro was employed for automatic extraction of average 
fluorescence signal for all bars in each set of barcode, and all the barcode profiles were compared to the 
number of cells by using the same program. Based on this data, heat maps were generated by using the 
software Cluster and Treeview(52). Flow cytometry data is analyzed in FlowJo software . P-values are 
calculated from two tail student’s T-test assuming unequal variance. 
Microchip Fabrication. The control layer was molded from a SU8 2010 negative photoresist (~20um in 
thickness) silicon master using a mixture of GE RTV 615 PDMS prepolymer part A and part B (5:1). The 
flow layer was fabricated by spin-casting the pre-polymer of GE RTV 615 PDMS part A and part B (20:1) 
onto a SPR 220 positive photoresist master at ~2000rpm for 1minute. The SPR 220 mold was ~17 µm in 
height after rounding via thermal treatment at 80 degree for 60 mins. The control layer PDMS chip was 
then carefully aligned and placed onto the flow layer, which was still situated on its silicon master mold, 
and an additional 60 mins thermal treatment at 80oC was performed to enable bonding. Afterward, this 
two-layer PDMS chip was cut off with access holes drilled. Finally, the microfluidic-containing PDMS 
slab was thermally bonded for 2 hours at 80 degree onto the barcode-patterned glass slide to give a fully 
assembled microchip. 
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Isolation, sorting and expansion of T cells. Briefly, enriched PBMC were applied onto a MART-1 
tetramer microarray. After 20 minutes incubation at 37 degree, unbounded cells were washed off and then 
attached MART-1 specific T cells were released from the array. In order to characterize low frequency 
antigen-specific T cells, 5 x 106 PBMC were expanded with irradiated and tumor antigen peptide-pulsed 
HLA-A*0201-transfected K562 (K562A2.1) used as antigen presenting cells (APC) at a ratio of 5:1 (51, 
53). The PBMC were cultured in AIM-V media plus IL-2 (300IU/ml) and CD3 antobidy (OKT3, 50ng/ml) 
on day 1, and then kept in culture for 24 days with IL-2 but without OKT-3. Irradiated (75 Gy) K562A2.1 
cells were pulsed with 10μg of peptide tyrosinase368-376 (YMDGTMSQV). The peptide-pulsed APCs were 
added weekly. After 30 days, expanded cells were sorted based on the same technique described above 
with Tyrosinase368-376/HLA-A0201 tetramer. 
On-chip secretion profiling. First, 200 ul 3% bovine serum albumin (BSA, Sigma) in phosphate buffer 
saline (PBS, Irvine Scientific) was flowed and dead-end filled into the chip to block non-specific binding. 
Second, a 200-µl cocktail containing all 12 DNA-antibody conjugates at 5 ug/ml in 3% BSA/PBS buffer 
was flowed through all microfluidic channels in 1 h at 37 degree. Then, 100µl of 3% BSA/PBS buffer 
was flowed into the device to wash unbounded DNA conjugated primary antibody solutions. THP-1 Cells 
were washed, stimulated with PMA/LPS or purified T cells acitivated with tetramer/anti-CD28 antibody 
or anti-CD3/anti-CD28 antibody in 10% FBS/RPMI-1640 media (ATCC) and loaded on chip within 5 
min in order to minimize pre-chip secretion. Then, the pneumatic valves were pressed down by applying 
20 psi constant pressure to divide 80 microfluidic channels into 1000 isolated microchammbers. Next, the 
chip was placed in a cell incubator (~37oC and 5% CO2) for 24 h (THP-1) or 12 h (T cells) to perform on 
chip secretion. Afterwards, the chip was removed from incubator and cells were quickly washed of the 
chip. A 200-µl cocktail containing all biotinylated detection antibodies was then flowed through the 
microchannels. The antibody concentrations are 5 ug/mL. Then, 200ul of the fluorescent probe solution 
(100 ng/ml Cy5-labeled straptavidin and 20 ng/ml C3-labeld M’ ssDNA) were flowed through to 
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complete the immuno-sandwich assay. Finally, the PDMS slab was peeled off and the microarray slide 
was rinsed with 1x PBS, 0.5xPBS and DI water twice, sequentially, and spin-dried. 
Culture and stimulation of THP-1 cells. THP-1 monocyte cells were (clone TIB 202) cultured in 
RPMI-1640 (ATCC) medium supplemented with 10% fetal bovine serum (FBS) and 10 μM 2-
mercaptoethanol. Cells grown close to the maximum density (0.8x106 cells/mL) were chosen for the 
experiment in order to minimize variation of cell cycles. Cells were washed and resuspended in fresh 
media at 2-4x106 cells/ml. Aliquots each containing 100 µL of cell suspension were prepared. 1µL of 
1mg/mL PMA and 1µL of 20µg/ml LPS were sequentially added into each aliquot to induced monocytic 
differentiation and stimulate TLR-4 activation. THP-1 cells activated with PMA and LPS exhibited a 
characteristic morphological change (Supplementary Figure 2). 
Melanoma adoptive transgenic T cell transfer clinical trial. Peripheral blood samples were obtained 
from patients with metastatic melanoma enrolled in a T cell receptor (TCR) transgenic ACT protocol 
(UCLA IRB# 08-02-020, IND# 13859, clinical trial registration number NCT00910650). A single 
baseline unmobilized leukapheresis processing two plasma volumes was performed to obtain PBMC, 
which were isolated by Ficoll-Hypaque (Amersham-Pharmacia) gradient centrifugation, for the 
generation of TCR transgenic cells and dendritic cell (DC) vaccines. Freshly collected PBMC were 
activated for 2 days by clinical grade anti-CD3 antibody OKT3 (50 ng/ml, anti-human CD3 FG purified 
OKT3, eBioscience) and human interleukin-2 (IL-2, 300 IU/ml, aldesleukin, Novartis). Following 
activation, cells are transduced in two consecutive days with a retroviral vector expressing the MART-1 
F5 TCR (MSGV1-F5AfT2AB vector), in plates coated with retronectin (Takara Bio Inc.) as previously 
described(54). The clinical grade retroviral vector MSGV1-F5AfT2AB was generated at the Indiana 
University Viral Production Facility starting from the master cell bank provided by Dr. Steven A. 
Rosenberg (Surgery Branch, NCI) as previously described(54). Patients were then admitted to the hospital 
and conditioned with a non-myeloablative, lymphocyte depleting chemotherapy regimen consisting of 
cyclophosphamide (60 mg/kg/day for two days, Mead Johnson & Company) and fludarabine (25 
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mg/m2/day i.v. daily for five days, Berlex). On study day 0 patients received up to 109 MART-1 F5 TCR 
transgenic T cells infused. MART-126-35 peptide pulsed DC were generated from cryopreserved PBMC 
following a one-week ex vivo differentiation culture in RPMI 1640 medium supplemented with 5% heat 
inactivated autologous plasma, 256 IU/ml of GM-CSF (Bayer) and 160 IU/ml of IL-4 (CellGenix) as 
previously described(55). On the day after TCR transgenic ACT, patients received an i.d. administration 
of up to 107 MART-126-35 peptide pulsed DC vaccines at a site close to a lymph node basin, and were 
started on systemic high dose IL-2 at 600,000 IU/kg i.v. every 8 hours for up to 14 doses as tolerated. 
Thereafter, patients stayed in the hospital until they had recovered from the chemotherapy-induced 
pancytopenia (median of 11 days).  
Synthesis of DNA-1o antibody conjugates. As-received antibodies were desalted, buffer exchanged to 
pH 7.4 PBS and concentrated to 1 mg/mL using Zebba protein desalting spin columns (Pierce). 
Succinimidyl 4-hydrazinonicotinate acetone hydrazone in N,N-dimethylformamide (DMF) (SANH, 
Solulink) was added to the antibodies at variable molar excess of (85:1) of SANH to antibody. Separately, 
succinimidyl 4-formylbenzoate in DMF (SFB, Solulink) was added at a 20-fold molar excess to 
5‘aminated 28mer oligomers in PBS. After incubation for 4 h at room temperature, excess SANH and 
SFB were removed and both samples buffered exchanged to pH 6.0 citrate buffer using protein desalting 
spin columns. A 20-fold excess of derivatized DNA was then combined with the antibody and allowed to 
react overnight at room temperature. Noncoupled DNA was removed using a Pharmacia Superdex 200 
gel filtration column (GE) at 0.5 mL/min isocratic flow of PBS. 
Fabrication of microfluidic-patterning chips. The microfluidic-patterning chips were made by molding 
a polydimethylsiloxane (PDMS) elastomer from a master template, which was prepared using 
photolithography to create a photoresist pattern on a Si wafer. An alternative was to make a silicon “hard” 
master by transferring the photolithographically-defined pattern into the underlying silicon wafer using a 
deep reactive ion etching (DRIE) process(56). The first method offers rapid prototyping, while the second 
method yields a robust and reusable mold, permitting higher throughput chip fabrication. The typical line 
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width and height are 20µm and 20µm, respectively. The PDMS elastomer-based microfluidic patterning 
chips were fabricated via a molding process. The mixture of Sygard PDMS (Corning) prepolymer and 
curing agent (10:1) was stirred, and poured onto the silicon mold which was pre-treated with trimethyl-
chloro-silane vapor to facilitate mold release. Next the PDMS poured on the mold was degassed for 30 
min via a house vacuum line, and then cured at 80oC for 1 h. The solidified PDMS slab was cut off the 
mold, assess holes drilled and then bonded onto a glass slide. Prior to bonding, the glass surface was pre-
coated with the polyamine polymer, poly-L-lysine (Sigma-Aldrich), to increase DNA loading. The 
coating process is described elsewhere18. The number of microfluidic channels determines the size of the 
barcode array. The completely microfluidic patterning chip contained of 13 parallel microchannels 
designed to cover a large area (3cm×2cm) of the glass slide for creating the DNA barcode microarray.  
Patterning of DNA barcode arrays. Using the microchannel-guided flow-patterning approach, we 
fabricated DNA barcode arrays that were at least 10-fold denser than conventional microarrays. 
Microcontact printing can generate high density arrays of biomolecules with spot sizes of a few 
micrometers (µms) (57, 58), but extending stamping to large numbers of biomolecules is awkward 
because of the difficulty in aligning multiple stamps precisely to produce a single microarray. Direct 
microfluidics-based pattering of proteins has been reported, but DNA flow-patterning with sufficient 
loading remains less successful compared to conventional spotting methods (59, 60). During the 
patterning of a DNA barcode array, solutions, each containing a different strand of primary DNA 
oligomers prepared in 1x PBS buffer, were flowed into each of the microfluidic channels. Then, the 
solution-filled chip was placed in a desiccator to allow solvent (water) to evaporate completely through 
the gas-permeable PDMS, leaving the DNA molecules behind. This evaporation process took from 
several hours to overnight to complete. Last, the PDMS elastomer was removed from the glass slide, and 
the barcode-patterned DNA was fixed to the glass surface by thermal treatment at 80oC for 4 hours. 
Potassium phosphate crystals precipitated during solution evaporation, but were readily removed by 
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rapidly dipping the slide in deionized water prior to bonding the blood-assay chip to the slide.  This did 
not affect the quality of the DNA barcode arrays. 
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Chapter 4 
Multifunctional T Cell Analyses to Study Response 
and Progression in Adoptive Cell Transfer 
Immunotherapy 
 
Summary 
Adoptive cell transfer (ACT) of genetically engineered T-cells expressing cancer-specific T cell 
receptors (TCR) is a promising cancer treatment. Here we investigate the in vivo functional activity and 
dynamics of the transferred cells by analyzing samples from three representative patients with melanoma 
enrolled in a clinical trial of ACT with TCR transgenic T cells targeted against the melanosomal antigen 
MART-1. The analyses included evaluating 19 secreted proteins from individual cells from 
phenotypically defined T cell subpopulations, and the enumeration of T cells with TCR antigen 
specificity for 36 melanoma antigens. These analyses revealed the coordinated functional dynamics of the 
adoptively transferred, as well as endogenous, T cells, and the importance of highly functional T cells in 
dominating the anti-tumor immune response. This study points to the need to develop approaches to 
maintain antitumor T cell functionality in order to increase the long term efficacy of TCR engineered 
ACT immunotherapy. 
In summary, a longitudinal functional study of adoptively transferred T cell receptor engineered 
lymphocytes yielded revealing snapshots for understanding the changes of antitumor responses over time 
in an adoptive cell transfer immunotherapy of patients with advanced melanoma. 
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Introduction 
A small percentage of patients with widely metastatic cancers can be cured with a variety of 
immune activating approaches. These dramatic, but infrequent, clinical responses are generally mediated 
by cytotoxic T lymphocytes (CTLs) that recognize tumor antigens through their T cell receptor (TCR). 
Adoptive cell transfer (ACT)-based therapies bypass many limitations of other cancer immunotherapies 
by generating ex vivo and then administering to patients large numbers of activated, tumor antigen-
specific effector cells. These cellular immune responses to cancer are mediated by CTLs specifically 
recognizing tumor antigens through their TCR. There are several classes of tumor antigens, including 
tumor-specific mutations, re-expressed cancer-testis antigens and lineage-specific antigens. Melanoma 
frequently expresses proteins of the pigmented pathway, reminiscent of its normal counterpart, the 
melanocytes, representing lineage-specific antigens such as tyrosinase, MART-1/Melan-A or gp100, 
which have been validated as targets for T cell responses to melanoma (61).   
Several groups have demonstrated that the treatment of patients with ACT therapy results in a 
high frequency of initial tumor responses (4, 62-66). When using T cells with multiple antigen 
specificities, such as when tumor infiltrating lymphocytes (TIL) are used for ACT transfer, tumor 
responses tend to be durable, sometimes lasting years (67). But TIL therapy is only feasible in a minority 
of patients who can undergo surgical resection of a metastatic lesion and have T cells in the biopsy that 
can be expanded in the laboratory. A potentially more widely applicable approach is the genetic 
modification of T cells obtained from peripheral blood. These blood cells can be modified to express 
natural TCRs or chimeric antigen receptors (CARs) that allow the specific recognition of tumor antigens. 
Early clinical experiences demonstrate that ACT using TCR-engineered T cells has antitumor activity in 
patients with metastatic melanoma and sarcoma (68-70). However, most of those responses have been 
transient, despite the persistence of circulating TCR transgenic cells in many cases (68, 69). This 
observation raises the question of whether these cells lose their antitumor functions, or if other 
components of the immune system are detrimentally influencing the therapy. As described in patients 
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with HIV infection, the quality of a T cell response is related to the functional performance of the T cells 
(17, 71, 72), which can be informatively analyzed at a single cell level with multiplexed technologies (10). 
Therefore, we conducted a detailed time-course analysis of patient-derived samples using newly 
developed multidimensional and multiplexed immune monitoring assays in selected patients receiving 
TCR engineered ACT therapy (10, 73). Our analyses revealed that coordinated, time-dependent 
functional changes of the adoptively transferred TCR transgenic cells and T cells with other antigen 
specificities, exhibiting changes that paralleled the clinical outcomes of the patients. This study points to 
the need to develop therapeutic approaches to maintain and foster antitumor T cell functionality in order 
to increase the long term efficacy of ACT immunotherapy. 
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Results 
Clinical protocol and patient characteristics 
In order to perform a detailed multidimensional analysis of immune function changes over time, 
and to study the response and resistance to ACT immunotherapy, we selected three out of 14 patients 
enrolled in a phase 2 clinical trial of MART-1 TCR transgenic ACT therapy. These three cases were 
selected based on their clinical course that are representative of the whole group, i.e. an initial transient 
tumor response followed by progression, and also based on the adequacy of samples to be analyzed in 
different assay platforms. All patients underwent a baseline leukapheresis to collect peripheral blood 
mononuclear cells (PBMCs), which were stimulated with anti-CD3 antibodies and IL-2 ex vivo for two 
days before undergoing two rounds of transduction with a retroviral vector carrying the high affinity 
MART-1-specific TCR termed F5 (69). With this approach, both CD4+ and CD8+ T cells were 
genetically engineered to express the MART-1-specific TCR. Cells were then cultured in IL-2 for three 
more days and were cryopreserved after lot release testing following the approved investigator new drug 
(IND) application #13859. Once the TCR transgenic cells were generated, patients were admitted to the 
hospital to receive conditioning chemotherapy with cyclophosphamide and fludarabine (69). This 
lymphodepletion procedure is designed to provide ‘space’ within the immune system for the TCR 
transgenic cells to expand, and is followed on day 0 with the reinfusion of up to 1 x 109 MART-1 TCR 
transgenic cells. On the next day, and on days 14 and 30 post-ACT, patients received three subcutaneous 
injections of 1 x 107 MART-126-35 peptide-pulsed dendritic cell (DC) vaccine generated from the same 
baseline leukapheresis product. They also received up to 14 doses of high dose-IL-2 at 600,000 IU/kg 
every 8 hours within the first five days post-ACT (Figure 1a and Table 1). The lymphodepleting 
chemotherapy and IL-2 administration were designed to maximize the ability of the infused TCR 
transgenic lymphocytes to homeostatically expand in vivo. The MART-126-35 peptide-pulsed DC vaccine 
was designed to provide antigen-specific stimulation based on our prior protocol optimization studies in 
mouse models (74). The above four components form a combined therapy approach that provides a 
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unified effector mechanism – the activated tumor-specific CTLs. Details on the patient characteristics, 
treatment delivery and outcomes for the three patients (F5-1, F5-2 and F5-8) studied herein are provided 
in Table 1.  
The adoptively transferred TCR transgenic lymphocytes undergo a rapid in vivo expansion and 
repopulate the peripheral immune system (peak frequency of >50%, 90 day persistence of >10%, Table 
1), with evidence of target specificity and antitumor activity (tumor reduction of 13-33%, Table 1). The 
repopulation of the immune system with the MART-1 TCR transgenic T cells resulted in an initial skin 
rash frequently centered on moles, systemic vitiligo (skin depigmentation) due to attack on MART-1 
specific melanocytes in the skin and hair follicles, and diffuse infiltration of CTLs into melanoma 
metastases (Table 1 and Figure 1b). 
 
 
Figure 1. The MART-1-TCR transgenic T cell ACT therapy. a. The boxes above the timeline show 
different modules of the therapy, with arrows pointing to the time they are administrated relative to day 0 
(the day of the infusion of the TCR-engineered T cells). Arrows below the timeline demonstrate the dates 
when blood samples are collected for different assays. b. Photo of one representative patient’s back with 
skin rash surrounding moles (top). In the immunohistochemistry staining of a tumor biopsy (bottom), 
CD8+ CTLs are stained as dark brown and melanoma cells are blue. 
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Table 1: Patient Demographics and Treatment 
Pt 
Study 
# 
Sex Age 
Prior 
Treatmen
ts 
Active 
Metastasis 
Sites 
Stage 
% 
MART-
1+ cells 
IFN-γ 
with 
K562-
A2-
MART-
1 
(pg/ml/
106) 
Peak % 
of 
MART-
1+ T 
cells 
Persisten
ce of 
MART-
1+ T 
cells 
# IL2 
doses 
adminis
tered 
Best % 
decrease 
of tumor 
sizes from 
baseline 
Toxicitie
s 
Respo
nse at 
EOS 
(day 
90) 
Skin 
and/or 
hair 
depigm
entatio
n 
Increas
ed TIL 
infiltrat
es 
F5-1 M 60 No 
Lung, 
Stomach, 
Liver, 
Pancreas, 
Peritoneum
, Soft 
tissues 
M1c 84.3 2.2 x 105 
57% at 
Day 9 
18.5% at 
3 months 12 -33 
Grade 3 
rash, 
NPF 
PD Yes Yes 
F5-2 F 46 
MKC 
prime-
boost 
vaccine, 
HD IL-2 
Skin, LN, 
Bone M1c 74.1 
1.5 x 
105 
59% at 
Day 9 
11% at 6 
months  6 -22 
Grade 3 
rash, 
NPF 
SD Yes Yes 
F5-8 M 44 No LN, Liver M1c 66.7 7.8 x 105 
51% at 
Day 7 
15.5% at 
5 months 11 -13 
Grade 3 
rash, 
NPF 
SD Yes NA 
 
Legend: M: Male; F: Female; LN: Lymph nodes; EOS: end of study; PD: progressive disease; SD: stable disease; NA: not available. NPF, 
Neutropenic fevers. 
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Integrated single cell functional analyses and antigen-specific CTL population 
enumerations 
To capture the time-dependent functional changes of the MART-1 TCR transgenic T cells and 
certain other T cell populations that could influence the therapy, we coupled our newly developed single 
cell barcode chip (SCBC) (10) with multi-parametric fluorescence activated cell sorting (FACS) (Figure 
2a and Supplementary Figure 1). This approach allowed us to interrogate the functional performance of 
phenotypically defined, antigen-specific T cells at the single cell level. We segregated CD4+ and CD8+ T 
cells with MART-1 specificity, as well as MART-1-negative T cells with a non-naïve phenotype, based 
on 10 cell surface parameters (Figure 2a). We then quantitated 19 cytokines and chemokines produced 
from single cells under stimulation using the SCBC microchip platform (Supplementary Figure 1), 
expanding on the 12-cytokine panel that we had used as a pilot panel for a previous paper (10). As an 
initial example of the potential of our SCBC chip, in that paper we reported the functionality of MART-
1+ T cells from patient F5-2 from study day 30 only, compared to blood lymphocytes from three healthy 
donors. The expanded and modified new panel used herein includes cytokines specific to CTL function 
(e.g. granzyme B), as well as cytokines characterizing T helper 1 (IFN-γ, IL-2), T helper 2 (IL-4, IL-5), T 
helper 17 (IL-17) and regulatory T (IL-10, TGF-β) cell functions (Supplementary Tables 1 and 2). 
We first compared the approach of FACS/SCBC with our previously described approach that 
coupled single-parameter NACS cell sorting (73) with SCBC functional analysis (10). The prior approach 
allowed for analysis of the MART-1 antigen-specific T cells, but did not permit the separation of the 
CD8+ and CD4+ components from the mixed population. The FACS/SCBC analysis permits such 
separation, but the FACS step requires a longer time prior to SCBC loading, which could lead to the loss 
of protein signal. Therefore, we tested the use of both antigen-specific and mitogen-based T cell 
reactivation in FACS/SCBC assays relative to antigen-specific reactivation in NACS/SCBC analyses 
(Supplementary Figure 2 and Methods) using MART-1+ T cells from a patient (F5-8) who had few 
CD4+ MART-1+ T cells. Both protocols revealed similar cytokine secretion profiles and time-dependent 
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functional changes, within the range of error bars. Thus, although there may be some signal loss 
associated with the FACS/SCBC assays, much of the critical information content is retained, and the 
significantly refined phenotype selection is a powerful advantage. 
The CD8+ MART-1-negative T cell population may contain populations that are specific to 
melanoma antigens other than MART-1. The detection of such populations has been attributed to epitope 
spreading, where T cells with antigen specificity other than the one induced by vaccination or ACT 
appear after tissue damage by the driver clone (75). Thus, we also monitored the frequency of 35 antigen 
specific sub-populations against previously described putative melanoma tumor antigens 
(Supplementary Table 3) using the NACS peptide/MHC tetramer assays (73). We also conducted 
multiplexed blood molecular marker assays based on samples from this clinical trial (Supplementary 
Figure 1). The blood assay results will be reported separately. 
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Figure 2. FACS scheme for purifying phenotypically defined T cells, and general properties of T 
cell functions. a. Multi-parametric FACS purification for selecting phenotypically defined T cell 
populations. A representative set of scatterplots are shown with the surface markers used and the cell 
frequency for each gating.  b. Hierarchical clustering of the 19 functional cytokines studied based on the 
single cell cytokine secretion measurement of CD8+ MART-1+ T cells from all three patients, and across 
all time points. Each functional group is identified and labeled (red).  Protein-protein correlations for 
proteins within the same group and across groups are given below the clustering map. c. One-dimensional 
scatterplots of three representative cytokines produced by single cells, separated by time points.  The 
dotted line represents the gate that separates cytokine-producing and non-producing cells. The 
percentages given above the plots denote the frequency of positive cells and the relative mean 
fluorescence intensity (MFI) of those cells relative to day 7. Each point represents a single cell assay.  The 
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points are color encoded (from purple to red) to represent the number of different proteins produced by 
each cell. The black trend line shows the total functional intensity of the positive cells for the specific 
cytokine plotted, computed as the frequency of positive cells, times their MFI. d. Ratio between the MFI 
(red line) and the molecular number of cytokines (blue line) for the polyfunctional T cells (cells with 5 or 
more functions) and all other cells, for each cytokine.  At far right are the mean and median values, 
averaged over all cytokines. 
 
 
Supplementary Figure 1. Scheme for the multiplexed immune monitoring study. a. NACS 
peptide/MHC tetramer microarray assays are used to enumerate the abundance of 35 melanoma-antigen 
specific T cell populations in PBMCs.  b. DEAL antibody microarrays are utilized to quantitatively 
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measure the levels of 37 blood protein markers from blood plasma. c. SCBC microchips are coupled with 
multi-parameter FACS (top) or with NACS (bottom) to permit the quantitative analysis of the levels of 19 
functional proteins secreted from phenotypically defined single T cells, based on 10 parameter (for 
FACS/SCBC) or 1 surface specificity (NACS/SCBC). For each sample, ~1400 experiments are conducted 
simultaneously. The FACS/SCBC permits study of highly refined phenotypically defined T cell 
populations, whereas NACS/SCBC assays select only for tumor-antigen-specific TCRs on the T cells, and 
so constitute a less-refined study.    
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Supplementary Figure 2. Comparison of results from NACS/SCBC and FACS/SCBC protocols for 
multiplexed single cell functional proteomic analysis. a. PCA analysis showing the plot of the first two 
components of the time-dependent changes of CD8+ MART-1+ T cells (FACS/SCBC) and MART-1+ T 
cells (NACS/SCBC) from F5-8. b. Mean intensity for each protein from the polyfunctional T cells of 
CD8+ MART-1+ T cells (FACS/SCBC) and MART-1+ T cells (NACS/SCBC) from F5-8 over time. 
These plots indicate that the two experimental protocols revealed similar trends. 
 
Supplementary Table 1. Antibody panel. 
Antibody Manufacturer 
IFN-γ R&D 
IL-10 R&D 
TNF-β R&D 
IL-4 eBioscience 
IL-5 R&D 
IL-1β eBioscience 
TGF-β1 R&D 
GM-CSF eBioscience 
TNF-α eBioscience 
IL-17A eBioscience 
Eotaxin R&D 
Granzyme B R&D 
IL-13 R&D 
IL-22 R&D 
MIP-1α R&D 
IL-2 R&D 
MIP-1β R&D 
IL-6 R&D 
TGF-β2 R&D 
 
Supplementary Table 2. Single cell cytokine panel and groupings of the functional protein 
identified by clustering. 
  CD8+ MART-1+ CD8+ MART-1-negataive 
CD4+ MART-1-
negative CD4+ MART-1+ 
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Proliferative 
IL-2 IL-2 IL-2 IL-2 
GM-CSF GM-CSF GM-CSF GM-CSF 
  IL-17A TNF-a IL-17A 
    IL-4 TNF-a 
Th2 
IL-4     IL-4 
IL-5     IL-5 
Regulatory 
IL-10 IL-10 IL-10 IL-10 
TGF-b2 TGF-b2 TGF-b2 TGF-b2 
IL-17A IL-22     
Inflammatory 
IL-6 IL-6 IL-6 IL-6 
IL-1b IL-1b IL-1b IL-1b 
IL-22 CCL-11 IL-17A IL-22 
  IL-5 IL-5   
Non-specific 
IL-13 IL-13 IL-13 IL-13 
TGF-b1 TGF-b1 TGF-b1 TGF-b1 
TNF-b TNF-b TNF-b TNF-b 
CCL-11   CCL-11 CCL-11 
      Granzyme B 
Antitumor 
Effector 
IFN-g IFN-g IFN-g IFN-g 
MIP-1a MIP-1a MIP-1a MIP-1a 
MIP-1b MIP-1b MIP-1b MIP-1b 
Granzyme B Granzyme B Granzyme B   
TNF-a TNF-a     
  IL-4 IL-22   
 
Supplementary Table 3. Melanoma antigen specific T cell populations studied. 
Tyrosinase1 NY-Eso1 MELOE-1 
Tyrosinase368 MAGE-A1 PRAME100 
MART-126 MAGE-C2191 PRAME300 
MART-132 MAGE-C2336 MMP-2 
gp100154 MAGE-3 Adipophilin 
gp100177 MAGE-A4 Survivin 
gp100209 MAGE-A10   
gp100280 CAMEL   
gp100457 HERV   
gp100476 SSX-2   
gp100619 TAG-1   
gp100639 NA-17   
TRP-2180 CDK-4   
TRP-2360 Prdx-5   
RAB38     
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General properties of T cell functional changes observed in ACT  
The 19 measured cytokines and chemokines studied represent a broad range of T cell functions 
(Figure 2b).  In order to capture general trends, we performed hierarchical clustering of each T cell type 
studied based on SCBC data from the three patients and all time points (Figure 2b and Supplementary 
Table 2). For the CD8+ MART-1+ T cells, we observed a primary clustering into antitumor effector 
functions (granzyme B, TNF-α, IFN-γ, etc.). Additional functions, such as regulatory (IL-10, TGF-β2) 
and pro-inflammatory (IL-6, IL-1β) are resolved with additional clustering (Figure 2b). Further analysis 
revealed that proteins within the same functional group exhibited a higher correlation than with proteins 
outside that group (Figure 2b bottom panel). These functional groupings are largely conserved across 
the four cell types studied (Supplementary Table 2). Thus, the T cells that we studied tend to exhibit 
coordinated behaviors. 
The cytokine readouts that we measured reflect the kinetics of the immune response process. As 
an example, Figure 2c and Supplementary Figures 3 present one-dimensional scatterplots of the 
cytokine production intensity of single CD8+ MART-1+ T cells from patient F5-1 over time. 
Supplementary Figure 4 show such changes for patients F5-2 and F5-8. Gates that separate protein 
secreting- and non-secreting cells are identified by comparing signals from empty chambers and 1-cell 
chambers. The percentage and mean fluorescence intensity (MFI) of granzyme B-producing cells 
decreased sharply within the first 30 days after ACT, whereas IFN-γ (Figure 2c) and TNF-α 
(Supplementary Figure 3) were most abundant at day 60. The chemokines MIP-1a (Figure 2c) and 
MIP-1b (Supplementary Figure 3) reflected time course features of both granzyme B and IFN-γ. Of note, 
IL-2 secretion remained low (< 3% positive cells) across all time points (Supplementary Figure 3). The 
total functional intensity for a given cytokine (defined as the % of positive cells × MFI, and plotted as the 
black line in Figure 2c) reveals again these two waves of the immune response after ACT, characterized 
by the production of granzyme B, IFN-γ and TNF-α, respectively. Additionally, unique functional 
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properties of the cell types studied are reflected in the cytokine measurements: three out of the four cell 
types studied could be easily distinguished based upon their cytokine profiles (Supplementary Figure 5). 
We noted that higher protein production levels were associated with cells that exhibit a higher 
polyfunctionality (Figure 2c). This feature is also quantitatively summarized in Figure 2d and 
Supplementary Table 4 for all measured cytokines, where we defined a polyfunctional cell as one 
producing 5 or more cytokines upon stimulation. Such cells typically make up only 10% of the population 
of a given cell type, but on average they secrete 100 times more copies of a given protein than do the 
remaining 90% of the population (Figure 2d).  The inference is that the highly functional T cells 
dominate (by about 10-fold) the anti-tumor immune response.  
Based upon the importance of the polyfunctional T cells, we defined a polyfunctional strength 
index (pSI) to summarize the observed T cell functional changes. For a given cell type, the pSI is 
calculated as the percentage of polyfunctional T cells relative to all CD3+ T cells, multiplied by the sum 
of the mean fluorescence intensity (MFI) of each of the 19 assayed cytokines from the polyfunctional 
subset. This index represents the total functional intensity contributed by all polyfunctional T cells of a 
given cell type, at a specific time-point. We further characterized pSI according to the types of 
coordinated functions that are revealed by hierarchical clustering. 
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Supplementary Figure 3. Changes of selected cytokines secreted by CD8+ MART-1+ T cells from 
F5-1. One-dimensional scatterplots of six representative cytokines produced by single cells, separated by 
time points.  The dotted line represents the gate that separates cytokine producing and non-producing cells. 
The percentages given above the plots denote the frequency of positive cells and the relative mean 
fluorescence intensity (MFI) of those cells relative to day 07. Each point represents a single cell assay.  
Those points are color encoded (from purple to red) to represent the numbers of different proteins 
produced by each cell. The black line shows the total functional intensity of the positive cells for the 
specific cytokine plotted, computed as the frequency of positive cells, times their MFI. 
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Supplementary Figure 4. Changes of selected cytokines secreted by CD8+ MART-1+ T cells from 
Patients F5-2 and F5-8. a-b. One-dimensional scatterplots of six representative cytokines produced by 
single cells, separated by time points for F5-2 and F5-8, respectively.  The dotted line represents the gate 
that separates cytokine producing and non-producing cells. The percentages given above the plots denote 
the frequency of positive cells and the relative mean fluorescence intensity (MFI) of those cells relative to 
day 07. Each point represents a single cell assay.  Those points are color encoded (from purple to red) to 
represent the numbers of different proteins produced by each cell. The black line shows the total 
functional intensity of the positive cells for the specific cytokine plotted, computed as the frequency of 
positive cells, times their MFI. 
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Supplementary Figure 5. Differences between different cell types studied. Cytokine secretion 
florescence intensity data, collected from the single cells functional assays, and collated for all time points 
and all three patients, was analyzed by principal component analysis. The first two components that 
jointly explain >50% of the data are plotted as the x- and y-axis. The four scatter plots highlight the 
individual single cell assays for each assayed T cell types. For each cell type, the points lie primarily 
along one direction.  These different directions represent specific set of functions, which are given in the 
key at left.  The ability of PCA to resolve the various phenotypes argues for the validity of the 
FACS/SCBC approach. 
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Supplementary Table 4. Functional differences of polyfunctional T cells and the rest T cells. 
In mean fluorescence intensity 
 
In mean molecular number 
 
 
  
IL2 IL17A IFNg TNFa IL13 TNFb CCL11 GB TGFb1 IL4 IL5 IL6 IL10 GMCSF TGFb2 MIP1a MIP1b IL22 IL1b Mean Median
MFI of 
polyfunctional 299 434 5220 6096 222 236 1546 4104 105 222 284 2742 189 1472 424 10922 9723 324 478 2371 434
MFI of the rest 36 39 152 227 35 47 195 789 36 23 68 38 15 7 36 1330 1358 63 48 239 47
Ratio 8 11 34 27 6 5 8 5 3 10 4 71 12 211 12 8 7 5 10 10 9
IL2 IL17A IFNg TNFa IL13 TNFb CCL11 GB TGFb1 IL4 IL5 IL6 IL10 GMCSF TGFb2 MIP1a MIP1b IL22 IL1b Mean Median
Mean 
molecule 
number of 
polyfunctional
2.3E+05 4.8E+05 6.9E+07 9.4E+07 1.2E+05 1.4E+05 6.0E+06 4.3E+07 2.8E+04 1.2E+05 2.0E+05 1.9E+07 9.0E+04 5.5E+06 4.5E+05 3.0E+08 2.4E+08 2.7E+05 5.8E+05 4.1E+07 4.8E+05
Mean 
molecule 
number of the 
rest
2.4E+03 2.8E+03 4.3E+04 9.6E+04 2.2E+03 4.0E+03 7.1E+04 1.2E+06 2.4E+03 9.4E+02 8.5E+03 2.8E+03 4.3E+02 9.0E+01 2.4E+03 3.3E+06 3.4E+06 7.5E+03 4.2E+03 4.3E+05 4.0E+03
Ratio 93 168 1599 978 55 35 85 37 11 132 24 6909 209 60546 192 92 70 36 137 96 118
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Time-dependent functional changes 
We analyzed the samples from the three patients to compare the functional dynamics of the CD8+ 
MART-1+ T cells (using the pSI) against the frequency and phenotypic changes of these cells, as well as 
changes in tumor burden (Figure 3). All three patients exhibited an initial reduction in tumor volume, 
followed by tumor regrowth, but with different times to tumor relapse (Figure 3a). On the other hand, the 
patients had evidence of engraftment of the TCR engineered cells (Figure 3b). The cells proliferated 
briskly following ACT by at least one log expansion in total cell numbers, and then diminished gradually. 
At least 109 MART-1+ T cells, which accounted for >10% of blood T lymphocytes, remained in 
circulation out to day 90 post-ACT. The cellular phenotyping, based upon cell surface marker expression, 
revealed relatively uniform changes among the three patients, from an early differentiation phenotype 
(naïve, central memory and effector memory) to a later differentiation phenotype (effector memory RA 
and effector) (Figure 3c, Methods and Supplementary Table 5).  
These observations contrast with the functional changes recorded for the polyfunctional T cells, 
as represented by the pSI plots of Figure 3d. These plots reveal large amplitude functional changes, as 
well as clear differences between the patients. For F5-1, at day 7 post-ACT, the CD8+ MART-1+ T cells 
predominately produced the cytotoxic molecule granzyme B, which accounted for >70% of the total 
functional intensity. However, by day 30, the pSI of these cells declined by around 100-fold. The 
functional strength of these cells begins to recover by day 45, but that recovery is accompanied by a 
different set of functions, including TNF-α, IFN-γ and inflammatory cytokines (such as IL-6), with no 
cytotoxic granule production. For F5-2, the CD8+ MART-1+ T cells only exhibited high antitumor 
effector functions (IFN-γ and TNF-α) after day 30. Patient F5-8 exhibited strong antitumor functions 
(granzyme B, IFN-g and TNF-a) initially that rapidly declined by day 30 post-ACT.   
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Figure 3. Time-dependent changes in tumor burden, and in number, phenotype, and function of 
CD8+ MART-1+ T cells.  Each row provides results for a different patient (F5-1, F5-2, and F5-8). a. 
Changes in tumor burden, as measured by a modified RECIST method (Methods). b. Changes of 
frequency (blue) and total number (green insert) of CD8+ MART-1+ T cells. c. Phenotypic changes of 
CD8+ MART-1+ T cells. The percentage of each T cell phenotype (naïve, central memory, effector 
memory, effector memory RA, effector) is represented by a different color. d. Functional changes (in pSI) 
of CD8+ MART-1+ T cells. Each cytokine function group is represented by a different color. For F5-2 
and F5-8, the y-axis is discontinuous to allow for large functional differences to be represented on the 
same graph. 
 
Supplementary Table 5. Antibody panel used for flow cytometry immunophenotyping 
analysis. 
Fluorchrome Tube a Tube b Tube c 
Pacific Blue CD8 (3B5)* 
FITC CD45RO (UCHL1)** CD279 [PD1] (MHH4)** CD28 (CD28.2)** 
PE Mart1 Tetramer*** 
Dump Channel 7AAD*** 
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ECD HLA-DR (Immu-357)*** 
CD45RA 
(2H4DHIILDB9)*** 
CD62L 
(DREG56)*** 
APC/AlexaFluor647 CD127 (hIL07R-M21)** CCR7 (3D12)** CD44 (G44-26)** 
AlexaFluor700 CD3 (UCHT-1)* 
APC-Cy7 CD25 (M-A251)** CD195[CCR5] (2D7/CCR5)** CD27 (M-T271)** 
PE-Cy7 CD4 (RPA-T4)$ 
In parenthesis the clone used for detecting the CDs. * Life Science; ** BDbioscience;*** Beckman 
Coulter; $ Biolegend.  
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The functional behavior of the other profiled T cell types also exhibited sharp time-dependent 
changes.  We present such data for patient F5-1 in Figure 4a-f.  Functional changes for patients F5-2 and 
F5-8 are shown in Supplementary Figures 6 and 7. A table that summarizes changes between day 60 
and day 07 for the three patients is provided in Figure 4g. The pSI of CD4+ MART-1+ T cells drops by 
~100-fold at day 7 post ACT and shows an unstable functional profile, switching from proliferative-
dominant (IL-2) at day 0 to antitumor effector-dominant (IFN-γ, TNF-α) on day 7, to inflammatory, 
regulatory and non-specific-dominant on day 30 (Figure 4a). We also recorded an accelerated 
disappearance of these cells, comparing to the CD8+ MART-1+ T cells (Figure 4b). A similar decrease 
in the pSI with functional shifting was observed for patient F5-8 (Supplementary Figures 7 and Figure 
4g). For F5-2, no cytokine production was detected from this T cell population. Thus, this group of 
unnatural T cells -CD4+ T cells expressing TCRs recognizing a MHC class I-restricted antigen- lacked 
the ability to proliferate and perform stable functions in vivo. 
The lymphodepletion and subsequent recovery process is reflected in the time-dependent 
functional changes of the MART-1-negative T cells (Figure 4c-f). For CD8+ MART-1-negative T cells 
from patient F5-1, the composition of the pSI is relatively unchanged across the 90 day period post-ACT, 
and exhibits cytotoxic and other anti-tumor functions throughout (Figure 4c).  At around day 30 post-
ACT, four populations attributable to epitope spreading were detected (Figure 4d). The presence of these 
populations was transient, diminishing again by day 72 post-ACT. Patient F5-2 presented similarities to 
F5-1. For example, a similar epitope spreading event and a durable, antitumor effector function-dominant 
pSI were both recorded for the CD8+ MART-1-negative T cell population of F5-2 (Figure 4g and 
Supplementary Figure 6). By contrast, patient F5-8, who had the lowest level of antitumor response, as 
well as a rapid tumor relapse (Table 1 and Figure 4g), presented no evidence for epitope spreading, and 
only a transient, anti-tumor pSI that had diminished by day 30 post-ACT (Figure 4g and Supplementary 
Figure 7).   
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In patient F5-1, the pSI of the CD4+ MART-1-negative T cells diminished during the 
lymphodepletion preconditioning and recovered by day 45. In absolute amplitude, the functional 
composition of these cells was relatively constant, and was dominated by proliferative functions (such as 
IL-2 and GM-CSF) (Figure 4e). However, starting around days 30-45, regulatory functions (TGF-β and 
IL-10) increased most significantly (by 27-fold relative to day 7) (Figure 4f and g).  This strong increase 
of regulatory functions in these non-TCR transgenic T cells was also noted in samples from patient F5-8 
as well at around day 60 (Figure 4g and Supplementary Figure 7). 
 
 
Figure 4. Functional changes of other T cell types for patient F5-1 over time and a summary of 
functional changes for all the three patients. a. Functional changes of the CD4+ MART-1+ T cells, 
plotted as a bar graph in pSI.  The total frequency of this phenotype is plotted as the orange background. 
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Each cytokine function group is represented by a different color. The percent composition of the functions 
is provided in the insert. b. The frequency ratio of CD4+ MART-1+ to CD8+ MART-1+ T cells. c. 
Functional changes of the CD8+ MART-1-negative T cells, with cell frequency presented as the orange 
background. d. Frequency of antigen-specific T cells recognizing melanoma antigen other than MART-1 
over the course of the therapy. The total frequency is plotted as the black line to provide an overall view 
of epitope spreading.  The frequency of each antigen specificity detected is provided in the insert, denoted 
by different colors. e. Functional changes of the CD4+ MART-1-negative T cells, with cell frequency 
presented as the orange background. f. Relative functional changes of the CD4+ MART-1-negative T 
cells normalized to those observed at day 7 by each cytokine group, along with cell frequency. g. A 
summary of functional changes for each T cell type analyzed across three patients. The ratio is calculated 
by the pSI for a cytokine functional group at day 60 relative to that at day 7. The patients are ordered 
according to increasing tumor relapse rate. The differences between patients in cell function (solid blue 
shapes) and in tumor burden (red shapes) are shown graphically in the table. 
 
 
Supplementary Figure 6. Functional changes of other T cell phenotypes for patient F5-2 over time. 
a. Functional changes of the CD8+ MART-1-negative T cells, with cell frequency presented as the orange 
background. b. The frequency of antigen-specific T cells recognizing melanoma antigen other than 
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MART-1 over the course of the therapy. The total frequency is plotted as the black line to provide an 
overall view of epitope spreading.  The frequency of each antigen specificity detected is provided in the 
insert, denoted by different colors. c. Functional changes of the CD4+ MART-1-negative T cells, with 
cell frequency presented as the orange background. d. Relative functional changes of the CD4+ MART-1-
negative T cells normalized to those observed at day 07, along with cell frequency. 
 
 
Supplementary Figure 7. Functional changes of other T cell phenotypes for patient F5-8 over time. 
a. Functional changes of the CD4+ MART-1+ T cells, plotted as a bar graph in pSI.  The total frequency 
of this phenotype is plotted as the orange background. Each cytokine function group is represented by a 
different color. The percent composition of the functions is provided in the insert. b. The frequency ratio 
of CD4+ MART-1+ to CD8+ MART-1+ T cells. c. Functional changes of the CD8+ MART-1-negative T 
cells, with cell frequency presented as the orange background. d. Functional changes of the CD4+ 
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MART-1-negative T cells, with cell frequency presented as the orange background. e. Relative functional 
changes of the CD4+ MART-1-negative T cells normalized to those observed at day 07, along with cell 
frequency. 
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Discussion 
Little is known about the mechanisms that lead to tumor progression after a response in patients 
receiving ACT immunotherapy. For many years the prevailing concepts were based on the outgrowth of 
tumor escape variants that down regulated the expression of tumor antigens or molecules of the antigen 
expressing machinery, or the pre-existence of mutant clones that were insensitive to immune cell attack 
(76). More recently, several experiences are pointing to direct adaptive responses of tumor resultant from 
the T cells themselves modulating the tumor target, with the tumors changing through a variety of 
mechanisms to become insensitive to CTL attack.  Examples include the up-regulation of PD-L1 (B7-H1) 
in response to interferons produced by tumor infiltrating T cells (77), or the antigen-specific T cells 
producing cytokines (i.e. TNF-α) that result in melanoma cells that express melanosomal antigens to 
dedifferentiate to escape (78). These are cancer cell-intrinsic mechanisms of resistance in response to 
adequately activated tumor antigen-specific T cells with full effector functions. A series of cancer cell-
extrinsic mechanisms of resistance to immunotherapy have also been postulated, with a major focus on 
the presence of immune suppressive cells in tumors. The role of regulatory T cells, indoleamine-2.3-
dyoxigenase (IDO) positive dendritic cells, and myeloid-derived suppressor cells (MDSC) in dampening 
immune responses in tumors has been well established in animal model systems and in patient-derived 
samples (79). Some of these immune suppressive cells are attracted or activated by the tumor-mediated 
secretion of immune suppressive factors, such as the transforming growth factor beta (TGF-β), vascular 
endothelial growth factor (VEGF) and certain other chemokines. 
The study of immune cell-intrinsic mechanisms of resistance has been limited by the complexity 
of repeatedly assaying immune functions over time, and has typically relied on assays quantifying the 
frequency of tumor-specific T cells, or through analysis of a single effector molecule, or through the 
analyses of surface proteins for identifying different T cell phenotypes. However, T cells produce a large 
amount of coordinated proteins in response to antigen recognition, and the breadth and depth of that 
immune response is guided by the spectrum and level of the proteins being produced (17). For example, it 
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has been previously shown in mouse models that the functional behavior of polyfunctional T cells best 
reflects the overall quality of an immune response (80), presumably because multiple T cell functions are 
needed to orchestrate a successful immune response.  
 In the current studies we interrogated T cell responses to cancer by applying new generation, 
multiplexed immune monitoring assays. These assays yield an unprecedented high resolution view of T 
cell functional dynamics in patient-derived samples. These are highly involved studies, and so we focused 
on extensively analyzing samples from three patients that exhibited different degrees of tumor response 
after ACT immunotherapy. Our studies suggest that there is an initial wave of cytotoxicity-dominated 
antitumor functions from adoptively transferred CD8+ MART-1-specific T cells. This leads to initial 
melanoma tissue destruction as detected by the decrease in the size of the metastatic lesions.  As has been 
noted in autoimmune diseases, this initial tissue destruction can lead to the expansion of T cells with 
specificity for other melanoma antigens, or epitope spreading (75). Epitope spreading within the 
population of the CD8+ MART-1-negative T cells was detected around day 30 in the two patients who 
had the best tumor responses, and that population of T cells retained robust antitumor functions out to at 
least day 90. However, the frequency of tumor-specific CTLs induced by epitope spreading was not 
maintained. One possibility, consistent with the data reported here, is that the CD4+ T cells, as they 
recover from the lymphodepletion regimen, may regulate and inhibit the anti-tumor immune response.  
This is also consistent with a report indicating that a deeper lymphodepletion regimen can improve the 
outcome for melanoma patients participating in TIL-based ACT trials (81).  
A number of factors based on properties of cell phenotype and persistence have been identified to 
associate with ACT therapy efficacy (67, 82). Our study supports the notion that T cell function is another 
important aspect that requires close scrutiny, since even when T cells show similar persistence and 
phenotypic changes in vivo, they can exhibit dramatically different functional profiles. Although the 
number of patients in this study was limited, each of the patients was very thoroughly investigated, to the 
extent that we can begin to associate some of the functional changes with differences in tumor relapse 
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between patients. As showed in Figure 4g, a strong gain (day 60 compared to day 7) of IFN-γ and TNF-α 
for CD8+ MART-1+ T cells, granzyme B and IFN-γ for CD8+ MART-1-negative T cells, antitumor 
effector and proliferative functions for CD4+ MART-1-negative T cells and a wider epitope spreading are, 
at least for this study, associated with a slower tumor relapse. By contrast, a strong gain of regulatory 
functions in CD4+ MART-1-negative T cells following their recovery from the lymphodepletion regimen 
appears to be associated with a corresponding faster tumor relapse (Figure 4g).  
These results suggest the need to incorporate strategies to maintain the functional properties of 
the TCR transgenic cells used for ACT therapies. These may include modifications of the culturing 
system to foster the generation of TCR transgenic cells with improved ability to persist functionally over 
time (83), pharmacological manipulations to provide more prolonged gamma-chain cytokine support 
(such as protracted low dose IL-2 administration), blockage of negative co-stimulatory signaling like 
CTLA4 or PD-1, or additional genetic engineering of the TCR transgenic cells to include cytokines or 
transcription factors that could maintain their function in vivo.  It is also clear that the endogenous T cells 
can expand and boost the antitumor immune response and can regulate or otherwise influence the 
function of the infused T cells. Understanding this biology, and learning to control it, appears to be an 
important research direction for ACT therapy. A broader application of these single cell functional 
analyses may prove valuable for probing the successes and failures across the spectrum of cellular 
immunotherapies. In particular, recent ACT trials that have utilized either engineered TCRs or CARs 
directed against antigens with better tumor selectivity than MART-1, have resulted in cases with complete 
regressions (62, 70). Directing the tools described herein towards analyzing those successes may provide 
powerful insights into how best to design such therapies. 
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Methods 
Clinical trial conduct Patients were enrolled in the clinical trial after signing a written informed consent 
approved by the UCLA IRB (#08-02-020 and #10-001212) under an investigator new drug (IND) filed 
with the US Food and Drug Administration (IND# 13859). The study had the clinical trial registration 
number NCT00910650. Eligible patients had MART-1 positive metastatic melanoma by 
immunohistochemistry (IHC) and were HLA-A*0201 positive by intermediate resolution molecular HLA 
testing. Objective clinical responses were recorded following a modified Response Evaluation Criteria in 
Solid Tumors (RECIST) (84), where tumor burden is quantified by the sum of the largest diameter of 
each tumor lesion measured either by PET/CT scan or physical exam. Skin and subcutaneous lesions 
evaluable only by physical exam were considered measurable if adequately recorded using a photographic 
camera with a measuring tape or ruler; there was no minimum size restriction for these lesions. 
Immunophenotyping and immunohistochemistry (IHC) Calculation of the absolute number of blood 
circulating MART-1-tetramer-specific T cells was performed by a dual platform method, combining the 
readout from flow cytometry and automated hematology analyzer (85). The flow cytometry-based MHC 
tetramer assay studies and the adaptation of a multicolor flow cytometry have also been previously 
described (86-88). T cells were classified using a panel of antibodies as described in Supplementary Table 
5. Naïve cells were classified as CD45+/CCR7+/CCR5-/PD1-, CD27+/CD28-/CD62L+, and 
CD45+/CCR7+/CCR5-/PD1+; central memory (CM) as CD45RO-/CD25-/HLA-DR-/CD127+; effector 
memory (EM) as CD45-/CCR7-/CCR5+/PD1+, CD45-/CCR7-/CCR5-/PD1+, CD45-/CCR7-/CCR5-
/PD1-, CD45-/CCR7-/CCR5-/PD1-, and CD27-/CD28-/CD62L-; effector memory RA (EMRA) in CD8+ 
as CD45RA+/CCR7-/CCR5-/PD1+, CD45RA+/CCR7-/CCR5+/PD1+; and effector as 
CD45RO+/CD25+/HLA-DR+/CD127-, CD45RO+/CD25+/HLA-DR-/CD127-, CD45RO+/CD25-/HLA-
DR-/CD127- (31, 89). Immunohistochemistry staining was performed following standard methods as 
previously described (48, 90). 
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Enumeration of antigen-specific T cells Our previously described peptide/MHC tetramer cell sorting 
approach (NACS) was used to enumerate antigen-specific T cells from cryopreserved PBMC obtained 
from patients through peripheral blood draws and leukaperesis as we have previously described (73). 
Briefly, NACS chips were generated by incubating p/MHC tetramer-ssDNA conjugate cocktail for 1 hour. 
Then 1 million PBMC were added on chip in RPMI medium for 20 minutes. Afterwards the slide was 
washed with RPMI medium and stained with CD3, CD4 and CD8 antibody cocktail for 30 minutes. Then 
the sample was fixed with PFA/PBS buffer for imaging with a Nikon TI florescence microscope (Melville, 
NY). The p/MHC tetramer was manufactured in-house. The method was shown to have good assay 
performance in comparison with flow cytometry analysis (73) (Supplementary Figure 8). The sensitivity 
of these NACS arrays to detect a particular tumor-antigen specific T cell population from all CD3+ T 
cells is about ~0.1% (73). 
Purification of phenotypically defined T cells We used two methods to purify T cells for SCBC 
functional assays. For the NACS/SCBC protocol, the MART-1+ or CD3+ cells were purified using 
p/MHC tetramer  or CD3 antibody as described above. Then cells were released and loaded on the SCBC 
chip within 30 minutes with MART-1 tetramer/CD28 antibody (10-7M and 2ug/ml, respectively) (91) or 
CD3/CD28 antibody (10ug/ml and 2ug/ml, respectively ) stimulation. 
For the FACS/SCBC protocol, the T cells were sorted using a BD ARIA II machine (Franklin Lakes, NJ). 
Cells were gated on FSC-A, FSC-H, SSC-A (for singlet, lymphocytes identification), 7-AAD (viability), 
CD3 (clone: UCHT-1), CD4 (OKT-4), CD8 (HIT8a), MART-1 tetramer, CD45RA (HI100), CCR7 
(G043H7). The machine was calibrated with BD positive and negative CompBeads before usage. Before 
sorting, PBMC had a viability of >80% and the four collected T cell populations were gated to achieve 
>95% viability and purity. The following cell populations were sorted and analyzed: CD3+CD4+MART-
1+, CD3+CD8+MART-1+, CD3+CD4+ non-naïve MART-1-negative and CD3+CD8+ non-naïve 
MART-1-negative. Naïve T cells were classified as CD45RA+ and CCR7+. Then the cells were washed 
before stimulation with MART-1 tetramer/CD28 antibody, MART-1 tetramer, CD3/CD28 antibodies or 
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CD3 antibody, respectively. The concentration used are: MART-1 tetramer (10-7M) (91), CD3 antibody 
(10ug/ml), and CD28 antibody (2ug/ml). All cell samples were also non-specifically stimulated with 
PMA (5ng/ml) and ionomycin (500ng/ml) given the long time and low-concentration staining required for 
FACS cell sorting before on chip functional assays that may lead to a low level of spontaneous cytokine 
production. However, these could be recovered by mitogen stimulation, as showed in Supplementary 
Figure 2.  
Integrated functional assays of single T cells We integrated upstream cell purification techniques with 
the SCBC (10) to enable the study of the functional proteomics from phenotypically defined single cells. 
The chips used here had a capacity of 1360 microchambers, and permitted the simultaneous measurement 
of 19 cytokines from single cells. The chip was first blocked with 3% BSA/PBS buffer, before hybridized 
with antibody-DNA cocktails (10). Each step takes an hour. After PBMC was stimulated and loaded onto 
an SCBC chip, the chip was imaged using high resolution bright field microscopy. Cells were incubated 
on chip for 12 hours at 37 degree in 5% CO2 cell incubator. Then they were rapidly washed out. The 
assay was completed by applying secondary biotinylated antibodies, streptavidin-cy3 and a final wash 
with 3% BSA/PBS buffer in sequence. Every step takes an hour. Finally, the slide was washed with PBS 
and 50/50 PBS/DI water in sequence before spin dried and scanned by a Molecular Devices GenePix 
4400A scanner (Sunnyvale, CA). Detailed calibration and validation has been provided previously, where 
the measurement accuracy (coefficient of variation) of any given protein within a single cell assay is ~10% 
(10), and the assay sensitivity is several hundred molecules (10). 
Computational algorithm and statistical analysis Custom routines written in the R software package 
were used to process, analyze and visualize the single cell functional assay results. The algorithm 
converts original scanned fluorescence images into data files containing the fluorescence intensities for 
each assayed protein within a given microchamber, and then matched them with the number of cells 
counted from videos of the chip collected. Data from empty chambers is used to measure the background 
level for each protein. This data was used to generate protein abundance histograms, which is fitted by 
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normal distributions and non-parametric methods, judged by Goodness of fit (92). The mean of the 
histogram, identified by the best fit, is used as the background level. Single cell data was then normalized 
by subtracting this background, so that different samples can be compared. The single cell data was then 
fitted by finite mixture models and the gate that separates the cytokine-producing and cytokine-non-
producing cells is identified (92, 93). To ensure robustness, the results were individually checked. These 
data were then used for subsequent hierarchical clustering and principal component analysis (93), as well 
as the analysis of the pSI of the cells.  Statistics and visual presentation was automatically generated by 
the algorithm. 
The polyfunctional strength index (pSI) is defined as total functional intensity contributed by all 
polyfunctional T cells of a given cell type, at a specific time point. Therefore, for a given cell type, the 
pSI is calculated as the percentage (%) of polyfunctional T cells relative to all CD3+ T cells, multiplied 
by the sum of the mean fluorescence intensity (MFI) of each of the 19 assayed cytokines from the 
polyfunctional subset, i.e. 
𝑝𝑆𝐼 𝑓𝑜𝑟 𝑎 𝑐𝑒𝑙𝑙 𝑡𝑦𝑝𝑒 𝑎𝑡 𝑎 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡= % 𝑜𝑓 𝑝𝑜𝑙𝑦𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ𝑖𝑛 𝑇 𝑐𝑒𝑙𝑙𝑠 
×  � 𝑀𝐹𝐼 𝑜𝑓 𝑐𝑦𝑡𝑜𝑘𝑖𝑛𝑒 𝑖 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑜𝑙𝑦𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑇 𝑐𝑒𝑙𝑙𝑠19
𝑖=1
 
Then, we further plot pSI as a segmented bar showing the contribution of each group of cytokines 
identified by hierarchical clustering. When comparing polyfunctional T cells with other T cells, 
fluorescence intensity is converted into molecular number using the calibration curves provided in (10). 
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Supplementary Figure 8. Validation of melanoma antigen specific T cell population enumeration 
assays. a. Images of cells captured by CD3 antibody, MART-1/HLA-A0201 tetramer, and other 
melanoma-antigen/MHC tetramer on a multiplex microarray (left). Micrographs of immunofluorescence 
staining of CD3, CD4 and CD8 conducted after the cell capture (right). b. Comparison of the p/MHC 
tetramer microarray approach (NACS) with flow cytometry p/MHC tetramer staining for determining the 
abundance, over time, of the MART-1 T cells from patient F5-2.  c. A comparison of NACS and FACS 
assays for the quantitation of the populations of other melanoma associated antigen-specific T cells from 
patient F5-2 on day 30 post-ACT. 
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Chapter 5 
KIR genes modify Crohn’s Disease susceptibility by 
reprogramming human natural killer cell function  
 
 
Summary 
Crohn’s Disease (CD) is a common chronic inflammatory disorder of the gastrointestinal tract.  
Killer cell Immunoglobulin-like receptors (KIRs) and Human Leukocyte Antigen (HLA) class I ligands 
are combinatorially associated with risks to CD and other chronic inflammatory diseases, but the 
underlying cellular mechanisms remain unknown. Here we show that the specific genetic combinations of 
KIR and HLA result in functional reprogramming of natural killer (NK) cells, known as ‘licensing’, that 
permits them to modulate the CD4+ T cell activation threshold ex vivo.  Single cell multiplex functional 
proteomics reveal that genetically licensed NK cells are polarized to robustly produce pro-inflammatory 
cytokines and chemoattractants, and these cytokines account for NK cell augmentation of CD4+ T cell 
proliferation.  Our findings revealed a new biologic paradigm to understand KIR-associated susceptibility 
to CD and other chronic inflammatory syndromes. 
In summary, KIR educated human NK cells promote a unique profile of cytokine production and 
T cell activation that indicate a mechanism for the Crohn’s Disease susceptibility. 
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Chapter 6 
Functional Heterogeneity Among Apparently 
Undifferentiated Hematopoietic Cells 
 
Summary  
The pool of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow are multipotent 
progenitors of the mature hematopoietic cells in the tissues of an animal’s body. The most immature but 
longest–lived of the bone marrow cells are the long-term HSCs, while the rest, including short-term HSCs 
and multipotent progenitor cells (MPPs), are  shorter lived(94, 95). However, other than being progenitors 
of mature cells that have functional activities, little is known about the effector function properties of 
HSPCs. Here we combine transgenic and genetic knockout mouse models with a microchip based single 
cell proteomics platform to show that, although long-term hematopoietic stem cells (HSCs) (defined as 
Lineage-cKit+Sca1+CD150+CD48-) do not secrete cytokines upon toll-like receptor (TLR) stimulation, 
LKS cells (defined as Lineage-cKit+Sca1+), a population including short-term HSCs and MPPs, can 
produce cytokines upon direct TLR-4 and TLR-2 stimulation. Within the population of LKS cells, we 
detect multiple functional subsets of cells, specialized in producing myeloid-like or lymphoid-like 
cytokine combinations. Moreover, we show that cytokine production by LKS cells is regulated by NF-κB 
activity, because p50-deficient LKS cells show reduced cytokine production while microRNA-146a 
(miR-146a)-deficient LKS cells show significantly enhanced cytokine production. Our results 
demonstrate a remarkable ability of phenotypically undifferentiated HSPCs to function as cytokine-
producing cells following activation of TLR/NF-κB signaling. Importantly, a portion of the LKS cells 
show a clear signature of myeloid/lymphoid differentiation branching even though they lack any known 
distinguishing surface markers. 
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Abbreviation list: ACT: Adoptive cell transfer; MFI: Mean fluorescence intensity; pSI: polyfunctional 
strength index; TCR: T cell receptor; CTL: cytotoxic T lymphocyte; TIL: tumor infiltrating T lymphocyte; 
CAR: chimeric antigen receptor; SCBC: single cell barcode chip; DEAL: DNA encoded antibody library; 
NACS: nucleic acid cell sorting; PBMC: peripheral blood mononuclear cell; IND: investigator new drug; 
DC: dendritic cell; FACS: fluorescence activated cell sorting;  
 
